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Introduction
Introduction
1.1 Hyaluronan (HA)
H Yaluronan (HA) was first described in 1934 by Mayer and Palmer as apolysaccharide found in vitreous body of bovine eye [Meyer and Palmer
1934]. Hyaluronan belongs to the family of glucosaminoglycans (GAGs). The
GAG family is defined by linear carbohydrate polymers consisting of disaccha-
ride units. In proteoglycans, protein cores are posttranslationally modified by
glycosyltransferases in the Golgi apparatus, where GAGs are added to pro-
tein cores. In contrast to the other GAGs, hyaluronan is not sulfated, lacks the
protein core and is synthesized on the plasma membrane [Fraser et al. 1997].
Hyaluronan is synthesized by addition of alternating N-acetylglucosamine and
D-glucuronic acid linked by β(1−4) and β(1−3) bonds (Figure 1.1). In average,
hyaluronan consists of approximately 25,000 disaccharide units, which is cor-
responding to 10 µm extended length [Fessler and Fessler 1966]. Hyaluronan
can range in size from 5 to 20,000 kDa in vivo.
Figure 1.1: Structure of Hyaluronan
2
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1.2 HA Metabolism
HA is synthesized by enzymes named hyaluronan synthases and degraded by
hyaluronidases. The turnover of HA in the human body occurs rapidly. Arround
one third of hyaluronan in the human body is turned over each day.
1.2.1 Hyaluronan synthases (HAS)
The mammalian hyaluronan synthases were cloned in 1996 and 1997. The first
cloned HAS was the murine HAS1, which was highly expressed in brain and to
a lesser extent in liver, skeletal muscle and pancreas [Itano and Kimata 1996a].
Later the same year, human HAS1 was isolated through screening of a human
cDNA library in an attempt to find cDNA clones that encode proteins, which
could bind to a T-cell lymphoma cell line [Shyjan et al. 1996]. Human HAS1
is the homologue of mouse HAS1 that shared 96% amino acid homology, and
developed from the same original gene. Northern blot experiments showed that
the human HAS1 mRNA is highly expressed in ovary [Shyjan et al. 1996].
In the same year, human and murine HAS2 were isolated by Spicer and
colleagues. The murine HAS2 is highly expressed in the mouse embryo and
in adult tissues such as brain, spleen and lung. Northern blot analysis showed
two bands at 3.2 kb and 4.8 kb [Spicer et al. 1996]. This indicates that there are
two transcriptional splicing variants for HAS2. However, no annotation for the
shorter splicing variant of HAS2 was entered to the Genbank database.
In 1997, Spicer and colleagues reported that the third HAS gene was de-
tected in both human and mouse named HAS3 [Spicer et al. 1997a]. They also
showed that there were two transcriptional splicing variants (6.5kb and 4kb) of
3
Introduction
mouse HAS3 by northern blot. In 2002, it was revealed that human HAS3 also
has two splicing variants [Sayo et al. 2002; Monslow et al. 2003]. Northern blot
analysis showed two bands of 4.8 kb and 2 kb.
In human and mouse, the three HAS genes are localized on different chro-
mosomes [Spicer et al. 1997b] and evidence indicates that gene duplication
induced the three HAS isoforms by evolution. After the first gene duplication,
HAS1 and HAS2 genes were formed. Then, the HAS1 gene was duplicated
to generate HAS1 pseudogene (found in Xenopus laevis, xHas-rs) and the
HAS3 gene is formed by HAS2 duplication, respectively [Spicer and McDonald
1998]. The HAS1 pseudogene could not yet be detected in mammals [DeAn-
gelis 1999]. Disruption of HAS2 causes embryonic lethality at E9.5 in mice,
whereas deletion of HAS1 and HAS3 showed no obvious phenotype during em-
bryonic development [Camenisch et al. 2002].
Topology of HAS isoforms
As in Figure 1.2, the HAS enzymes are localized in the plasma membrane and
the topological prediction shows that they span the membrane seven times with
the active site presumably located in the large cytoplasmic loop [Weigel et al.
1997]. Studies on raw membrane preparations showed that the sugars were
added to the reducing end of the chain [Weigel et al. 1997; Asplund et al. 1998;
Itano and Kimata 1996b]. The enzymatic activity of hyaluronan synthases is ref-
ered to the glycosyltransferase of both glucoronic acid and acetylglucosamine.
Site directed mutagenesis experiments showed that the active center of HAS
likely resides in the large intracellular loop between the second and the third
transmembrane domain [Yoshida et al. 2000]. Polymerization of HA is thought
to occur at the cytoplasmic active center of HAS and the growing polymer is
4
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Figure 1.2: Predicted topological structure of eukaryotic and bacterial hyaluronan syn-
thases.
Very similar hydropathy plots and primary structure (28 - 71 % identity) among all the HAS
isozymes suggest that they are similarly organized within the membrane. The scheme depicts
the N- and C-termini and the large central domain, between MD2 and MD3, inside the cell. The
larger eukaryotic HASs (red line) have additional amino acids in all regions compared to the
bacterial HASs (green line), except for the highly conserved 178 amino acids carboxyl terminal
of the central domain and MD1-MD5. In particular, the carboxyl terminal ∼25 % of the eukary-
otic HASs has two additional predicted membrane domains (MD6 and MD7), missing in the
bacterial proteins. The conserved Cys is indicated by the circled C. MD5 can be modeled as
an amphipathic helix, which orients the C terminus of all HAS members inside. (Modified from
[Weigel et al. 1997])
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extruded to the outside of the cell during elongation. HA is exported to the ex-
tracellular matrix either by the HAS enzyme itself or through one of the ABC
transporters or the combination of both [DeAngelis and Weigel 1994; DeAngelis
and Achyuthan 1996; Schulz et al. 2007; Prehm and Schumacher 2004].
Activity of HAS isoforms
All three HAS isoforms catalyze the same reaction. Even though, each HAS
isoform produces HA of different length with different enzymatic kinetics [Itano
et al. 1999a]. HAS1 and HAS2 produce high molecular weight (HMW) HA with
the average size of 2× 106 Da, wherease the product of HAS3 is about 2× 105
Da in size [Spicer et al. 1997a; Itano et al. 1999a; Brinck and Heldin 1999]. In
vitro study indicated that HAS enzyme could polymerize 10 - 100 UDP sugar
precursors per second [DeAngelis 1999]. Thus, it takes a HAS enzyme 5 - 10
minutes to produce HA chain with 1 - 10 × 106 Da in length in vitro.
Splicing variants of HAS3
Two splicing variants of human HAS3 were discovered, namely HAS3v1 and
HAS3v2. Figure 1.3 A shows the genomic structure of human HAS3 gene an-
notated in the Genbank. HAS3v2 spreads longer on the genome than HAS3v1.
Thus, HAS3v1 consists of 553 AA while HAS3v2 is only 281 AA in length.
This is due to the fact that the coding sequence on the last exon of HAS3v2
is shorter. The difference in the 5’ UTR (untranslated region) between HAS3v1
and HAS3v2 indicates the diverse transcriptional regulation. HAS3v1 and HAS3v2
share the first two coding exons, which causes that the first 246 amino acid from
HAS3v1 and HAS3v2 are identical. Homology analysis reveals that HAS3v2 is
6
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Figure 1.3: HAS3v1 and HAS3v2 are close related
(A): Genomic structure of HAS3 splicing variants; (B): Homology analysis of HAS isoforms.
closer related to HAS3v1 than HAS2 and HAS1(figure 1.3 B). No report has yet
addressed human HAS3v2 except the first detection [Sayo et al. 2002; Monslow
et al. 2003].
1.2.2 Hyaluronidases (HYAL)
Enzymes that are capable to degrade hyaluronan are known as hyaluronidases.
There are six genes in mammals that encode hyaluronidases. These six hyaluronidase
7
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Chromosomal
cluster
Gene Protein Degradation
product of
HA
physiological ex-
pression pattern
Optimal PH
3p21.3
Hyal1 Hyal1 tetra-&
hexa-
saccharides
serum, liver, kid-
ney, heart
3-4
Hyal2 Hyal2 20kDa liver, kidney,
heart, placenta
4
Hyal3 Hyal3 n.d. bone marrow,
testis
n.d.
7p31.3
Hyal4 Hyal4 - n.d. n.d.
SPAM1 PH20 tetra-&
hexa-
saccharides
Testis 4.5, 7.5
HyalP1 None - - -
Table 1.1: The six hyaluronidase paralogues in human genome
n.d.-not determined
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genes are localized to two gene clusters on the chromosomes 3p21 and 7q31
in human.
Hyaluronidase 1 (HYAL1) is originally isolated from serum [Frost et al. 1997].
The molecular weight of human Hyal1 is 45 kDa after translation, and 8 kDa is
added by the post-translational glycosylation. The enzymatic activity of HYAL1
is optimal at an acidic pH. HYAL2 is approximately 40 % paralogous to HYAL1.
HYAL2 can only cleave hyaluronan into an intermediate size (about 20 kDa).
In mice, HYAL2 is expressed in the brain during the fetal development and si-
lenced after birth [Strobl et al. 1998; Lepperdinger et al. 2001]. This indicates
the HYAL2 plays an important role in embryonic development of brain. HYAL2
can attach to the surface of cell membrane as a GPI anchored protein, which
may work as a receptor for an oncogenic virus, namely Jaagsiekte sheep retro-
virus [Rai et al. 2001]. PH20 is expressed in the testis in two forms. During the
fertilization, one form of PH20 is localized on the surface of the acrosomal head
of the sperm to enable the sperm to penetrate the HA-rich ECM of the cumulus
cells surrounding the egg. Then, the other form of PH20, which is localized in
the acrosomal vesicle, is required for the sperm to degrade the surface associ-
ated HA and to bind to the surface of the egg cell [Kreil 1995]. Table 1.1 shows
the known enzymatic properties of human hyaluronidases.
The mammalian hyaluronidases function as β-endo-N-acetyl-glucosaminodases,
which degrade not only hyaluronan but also other GAGs such as chondroitin sul-
fate and dermatan sulfate [Batra et al. 1997]. To date, the HA specific hyaluronidases
are only discovered in Streptococci Pneumococcus and Streptomyces hyalurolyti-
cus.
9
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Figure 1.4: Pericellular hyaluronan coat
Chondrocytes were fixed and incubated with uranyl acetate in suspension, then examined using
ESEM (environmental scanning electron microscopy). (A) Untreated cells are surrounded by
a 4.4 ± 0.7-mm-thick hyaluronan coat (arrow). (B) Hyaluronidase removed the pericellular
hyaluronan coat competely. Scale bar, 5 mm. [Zaidel-Bar et al. 2004]
1.3 Localizatioin of HA
1.3.1 Extracellular hyaluronan
Hyaluronan is a key component of the extracellular matrix (ECM). During syn-
thesis, the growing polymer chain is extruded through the membrane into the
pericellular space. After synthesis, hyaluronan can be retained on the cell sur-
face to form a voluminous pericellular matrix (pericellular coat). Figure 1.4
shows the hyaluronan dependent pericellular matrix in Chondrocytes [Zaidel-
Bar et al. 2004]. This pericellular hyaluronan matrix plays multiple roles in cell
adhesion/detachment, and cell shape changes associated with proliferation and
locomotion. By overexpressing the hyaluronan synthases, microvillous mem-
brane protrusions were observed that form the scaffold of hyaluronan coats in
certain cells [Rilla et al. 2005; Kultti et al. 2006]. Hyaluronan is crosslinked by
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various proteins, such as aggrecan, TSG-6, inter-alpha-trypsin inhibitor, versi-
can and brevican [Day and Prestwich 2002]. This enables hyaluronan to gain
different functions such as inflamatory response.
1.3.2 Intracellular hyaluronan
In 1976, it was first reported by Margolis and colleagues that glycosaminogly-
cans are enriched in the rat brain nuclei and hyaluronan accounts for nearly 1/3
of the total quantity [Margolis et al. 1976]. Intense HA staining was observed in
rough endoplasmic reticulum (rER) membranes (but not lumen), plasma mem-
branes, and nuclei in all the tissues studied [London˜o and Bendayan 1988; Kan
1990; Ripellino et al. 1988; Eggli and Graber 1995]. Intracellular HA can be
accumulated under hyperglycemia condition [Wang and Hascall 2009]. Evanko
and Wight showed that HA accumulated intracellularly in the perinuclear region
of aortic smooth muscle cells during the premitotic and mitotic stages [Evanko
and Wight 1999]. However, the source of the intracellular HA is not yet clear. A
recent study treated viable smooth muscle cells with hyaluronidase to remove
pericellular HA to pervent the internalization. This eliminated most but not all of
the intracellular HA. This supports the conclusion that a large proportion might
be due to endocytosis uptake. Further, exogenous fluorescein-labeled hyaluro-
nan was taken up into vesicles in growing cells but was localized distinctly com-
pared to endogenous hyaluronan, suggesting that hyaluronan in cells may be
derived from an intracellular source [Evanko and Wight 1999].
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1.3.3 Intracellular hyaladherins
The identification of intracellular HA-binding proteins (IHABPs), including RHAMM,
IHABP4, CDC37 and HABP1, lends additional support to the existance of intra-
cellular HA [Day and Prestwich 2002; Assmann et al. 1998; Hofmann et al.
1998; Huang et al. 2000; Turley et al. 2002]. RHAMM is one of the well-studied
HA receptors. The precise function of RHAMM is described in a subsequent
section (see section 1.4.2). Human IHABP4 is 57 kDa in size. IHABP4 is a
cytoplasmic and nuclear protein that can be phophorylated on serine and thero-
sine residues. IHABP4 could bind to hyaluronan as well as chondroitin sulfate,
heparane sulfate, and RNA though with low affinity. The IHABP4 expression is
enriched in some tumor cells [Kobarg et al. 1997]. IHABP4 was shown to asso-
ciate with RACK1/PKC pathway for regulating the cellular functions [Nery et al.
2004]. In 1995, Grammatikakis and colleagues showed that cell cycle control
protein, CDC37, could bind to hyaluronan, chondroitin sulfate and heparin in
vitro [Grammatikakis et al. 1995]. It still unknown whether cell division could be
modified by cdc37 after binding to HA. HABP1was first isolated from rat kidney
by HA sepharose affinity chromatography [Gupta et al. 1991]. The GAG bind-
ing affinity of HABP1 is restricted to hyaluronan. HABP1 coated culture plates
allowed more cell to attach [Gupta and Datta 1991]. Subcellularly, HABP1 lo-
calized in the mitochondrial matrix, cytoplasma, nuclear and also on the plasma
membrane [Gupta et al. 1991; Muta et al. 1997; Dedio et al. 1998; Simos and
Georgatos 1994]. Activated ERK, one of the MAP kinases, can phosphorylate
HABP1 [Majumdar et al. 2002]. Phorbol 12-myristate 13-acetate (PMA) can
derease HABP1 in cytoplasma with parallel increase in the nucleus by activating
ERK. This indicates that HABP1 contributes in part to the MAP kinase cascade
implying a broad role in signaling. Furthermore, HABP1 was up-regualted at
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both mRNA and protein level during cisplatin and TNF-alpha-induced apoptosis
[Kamal and Datta 2006; Guo et al. 1999]. Ectopic expression of HABP1 induces
apoptosis, autophagic vacuoles and mitochondrial dysfunction [Meenakshi et al.
2003; Sengupta et al. 2004; Chowdhury et al. 2008]. Overexpression of HABP1
was observed in a variety of adenocarcinomas including thyroid, colon, gastric,
esophageal and lung adenocarcinoma [Rubinstein et al. 2004].
1.4 Physiological function of HA
1.4.1 Physical function of HA
HA has diverse functions despite of its unbranched simple composition. The
axial hydrogen atoms create a non-polar, relatively hydrophobic core while the
equatorial side chains produce a more polar, hydrophilic surface, thereby induc-
ing a twisting ribbon structure. As a result, the hyaluronan molecule can ran-
domly fold to coiled structure under physiological conditions and occupy a very
large space [Scott et al. 1991]. HA binds a huge amount of water in the extra-
cellular space and thus hydrates tissues and skin dermis. Hyaluronan regulates
water balance, osmotic pressure and acts as an ion exchange resin. Further-
more, HA forms a thin layer in the luminal surface of blood vessel, named apical
glycocalyc that excludes certain macromolecules,leukocytes and pletelets from
direct interaction with the luminal surface of endothelial cells [Henry and Duling
1999]. As a lubricant and a shock absorber, hyaluronan acts as a structural
molecule in the vitreous humor of the eye, in joint fluid, and in Wharton’s jelly
[Toole 2004].
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1.4.2 HA receptors and intracellular signaling pathways.
It is now known that HA plays an important role in modulating cell behavior.
Hyaluronan regulates cell motility, cell-cell and cell-matrix adhesion, cell prolif-
eration and differentiation. It participates in fundamental processes such as em-
bryological development and morphogenesis [Toole 1990, 2001], wound healing
[Weigel et al. 1988; Longaker et al. 1991], repair and regeneration and inflam-
mation [Noble 2002; De la Motte et al. 2003; Majors et al. 2003]. HA regulates
the intracellular signaling pathways by binding to the proteins known as hyal-
adherins including LYVE1 (Lymphatic Vessel Endothelial Receptor 1), HARE
(Hyaluronan Receptor for Endocytosis), toll-like receptors TLR and TLR4, CD44
(Cluster of Differentiation 44) and RHAMM (Receptor for Hyaluronan Mediated
Motility).
RHAMM
RHAMM localizes both intracellularly and on the outer plasma membrane, al-
though, there is no signal peptide or transmembrane domains encoded [Turley
1980]. Intracellularly, RHAMM exists in the cytoplasm, mitochondria and nu-
cleus [Assmann et al. 1999; Crainie et al. 1999; Entwistle et al. 1996; Lynn et al.
2001]. RHAMM interacts with cytoskeleton, microtubules, centrosomes and mi-
totic spindle [Assmann et al. 1999; Maxwell et al. 2003]. RHAMM is engaged in
different cellular functions including cell transformation and proliferation. Over-
expression of RHAMM leads to ras-dependent cell transformation in fibroblasts
[Hall et al. 1995]. It also influences cell mitosis by inducing the expression of
cdc25 and cyclin B1, which are both involved in cell cycle regulation [Mohapa-
tra et al. 1996]. The expression of RHAMM is also differentially regulated during
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the different phases of the cell cycle [Sohr and Engeland 2008]. The mRNA and
protein levels of RHAMM are elevated during the S-phase and peak during the
mitotic phase (G2/M). HA accumulates during the mitosis for cell detachment
[Brecht et al. 1986]. Further, RHAMM expression can be down-regulated by the
tumor suppressor P53. Therefore, HA-RHAMM interaction might play an impor-
tant role in cell cycle regulation and thereby RHAMM is significantly involved
in cancer progression. A current model of HA-dependent RHAMM mediated
signaling pathways is demonstrated in figure 1.5 [Turley et al. 2002].
The basal expression level of RHAMM is low in normal tissues [Turley et al.
2002; Evanko et al. 2007; Slevin et al. 2007]. Deficiency of RHAMM in mice
showed no obvious effect on embryonic development and adult mouse home-
ostasis but revealed delayed wound healing [Crainie et al. 1999; Nedvetzki et al.
2004; Tolg et al. 2006]. However, up-regulation of RHAMM was reported in sev-
eral advanced cancers [Giannopoulos and Schmitt 2006; Hus et al. 2008; Rein
et al. 2003; Tolg et al. 2003; Yamano et al. 2008; Zlobec et al. 2008]. For ex-
ample, RHAMM is defined as a breast cancer susceptibility gene [Pujana et al.
2007]. The interaction between HA and RHAMM activates multiple signaling
pathways that affect the motility and progression of breast cancer cells [Turley
et al. 2002]. Higher expression of RHAMM in breast cancer is associated with
poorer clinical prognosis and higher risk of lymph node metastasis [Assmann
et al. 2001; Wang et al. 1998].
CD44
CD44 belongs to the class 1 transmembrane glycoprotein family and functions
as a ubiquitous cell surface receptor of hyaluronan. CD44 is a single copy gene
and highly conserved [Screaton et al. 1992]. CD44 transcripts are subject to
15
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Figure 1.5: HA-dependent RHAMM mediated signaling pathways
RHAMM is a hyaladherin that occurs in multiple subcellular compartments and that can also
be exported to the extracellular milieu where it binds to the cell surface. Cell surface RHAMM-
hyaluronan interactions regulate signaling through Ras and Src. Cell surface RHAMM stim-
ulates the PDGF receptor to activate Erk kinase, a key map kinase involved in cell motility.
Intracellular RHAMM proteins encode multiple kinase docking and recognition sites, and an
intracellular form of RHAMM has been shown to physically associate with Erk1 kinase. In-
tracellular forms also associate with the cytoskeleton, notably interphase and mitotic spindle
microtubules. The ability of intracellular RHAMM to associate with multiple signaling complexes
and to associate with the cytoskeleton suggest that RHAMM functions as adapter proteins like
vinculin and paxillin. FAK, focal adhesion kinase. (Modified from [Turley et al. 2002])
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alternative splicing, which affects predominantly the extracellular membrane-
proximal nast of CD44 proteins [Stamenkovic et al. 1991; Gu¨nthert et al. 1991].
The standard isoform of CD44 consists of an N-terminal signal sequence (exon
1), a HA binding domain with homology to the link protein family of aggrecan
and HA binding proteins (exons 2 and 3), a stem region of 248 amino acids
(Exons 4, 5, 16, 17), a 21 amino acid transmembrane domain (exon 18), and a
72 amino acid cytoplasmic domain (exon 19). The splice variants are generated
as a result of insertion of various permutations and combinations of exons 6-15
(v1-v10) into the stem region. CD44 isoforms are broadly expressed and range
form 80 to 200 kDa in size. The mRNA and protein structures of CD44 splicing
variants are shown in figure 1.6. The variants are most commonly expressed
in epithelial cells and are upregulated under pathological conditions such as
cancer [Screaton et al. 1992; Stamenkovic et al. 1991; Goldstein and Butcher
1990].
CD44 can be regulated at multiple levels: promoter methylation, transcrip-
tion, post-translational modifications such as glycosylation, glycosaminoglycan
interaction, and phosphorylation, ligand binding, and proteolytic processing of
the extracellular domain [Lou et al. 1999; Verkaik et al. 1999; Yan et al. 2003;
Borland et al. 1998; Greenfield et al. 1999; Zhang et al. 1995; Legg et al. 2002;
Neame and Isacke 1992; Cichy and Pure´ 2003]. The binding of CD44 isoforms
to hyaluronan contributes to the stimulation of aggregation, proliferation, mi-
gration, and angiogenesis [Lesley et al. 1993; Bourguignon et al. 1992, 1998;
Lokeshwar et al. 1996]. The intracellular domain of CD44 isoforms selectively
interacts with cytoskeletal proteins and regulates specific signalings such as PI
3 kinase pathway [Bourguignon et al. 1998]. Therefore, CD44 isoforms directly
link with hyaluronan and the cytoskeleton. Figure 1.6 summarizes the signal
cascades, which are regulated by hyaluronan-CD44 interaction.
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Figure 1.6: HA-dependent CD44 mediated signaling pathways
CD44-hyaluronan interactions promote tyrosine kinase (TK) activity of HER2 and the non-
receptor kinase, Src. Src phosphorylates cortactin, which recruits it to the cell membrane.
CD44-hyaluronan interactions also activate RHOA and Rac1, and CD44 binds to Tiam1 and
Vav2. Hyaluronan binding also causes the association of CD44 forms with cytoskeletal proteins
such as ankyrin and ERM proteins. The current model suggests that the close interactions
between CD44 and its selected binding partners play a pivotal role in coordinating cross-talk
among various intracellular signaling pathways (e.g. Rho/Ras signaling and receptor-linked
(p185HER2)/non-receptor-linked (c-Src) tyrosine kinase pathways) leading to the concomitant
onset of multiple functions such as tumor cell adhesion, proliferation/growth, migration, and
invasion. MLC, myosin light chains. (Modified from [Turley et al. 2002])
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1.5 Hyaluronan in cancer
Hyalronan is shown to be elevated in both the cancer epithelium and peritumoral
stroma during cancer progression depending on the cancer type. Either is as-
sociated with an unfavorable outcome of the disease. Recently, it is shown that
hyaluronan is not only a prognostic indicator but also a novel target of therapy
[Nakazawa et al. 2006; Pa´lyi-Krekk et al. 2007].
Tumor hyaluronan is correlated with the mRNA expression level of HAS iso-
forms [Pienimaki et al. 2001; Karvinen et al. 2003; Pasonen-Seppa¨nen et al.
2003]. This indicates that transcriptional regulation may play an important role
in determining the hyaluronan accumulation. HAS isoform expression is stimu-
lated by growth factors like EGF, KGF and PDGF [Pienimaki et al. 2001; Karvi-
nen et al. 2003; Pasonen-Seppa¨nen et al. 2003; Jacobson et al. 2000]. Further-
more, the expression levels of both growth factors and their receptors are fre-
quently induced in cancers. Growth factors from cancer and stromal cells may
act in convert to stimulate hyaluronan synthesis [Jacobson et al. 2000]. Specifi-
cally, cancer cells may induce the stromal cells to produce a HA-enriched tissue
structure, which is more appropriate for tumor growth [Knudson and Toole 1988;
Edward et al. 2005]. On the other hand, growth factors from stromal cells could
stimulate cancer cell migration [Karnoub et al. 2007].
The malignant transformation of cells is frequently associated with aberant
HA synthesis and ECM gene expression [Weigel et al. 1997; Itano and Kimata
2002; Stern et al. 2006]. Both HAS1 and HAS2 expression are elevated in
highly malignant cells transformed with v-src. This implies that HAS isoforms
may be involved in different stages of malignant transformation although the
HAS enzymes are not transformed by themselves [Toole 2004]. Furthermore,
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overexpression of HAS2 and HAS3 genes resulted in HA over-production and
increased tumorigenicity of fibrosarcoma, melanoma, and mesothelioma cells
[Kosaki et al. 1999; Liu et al. 2001; Itano et al. 1999b]. The importance of HAS
enzymes for tumor cell phenotypes is also supported by the finding that sup-
pression of HAS2 or HAS3 diminished the tumorigenic potential in a variety of
tumors [Koyama et al. 2007; Zoltan-Jones et al. 2003; Desmoulie`re et al. 2004;
Lo¨hr et al. 2001]. Elevated HAS1 expression and intronic gene splicing correlate
with poor prognosis in human colon cancer, ovarian cancer, and multiple myelo-
mas [Itano et al. 2004; Theocharis et al. 2003; Itano et al. 2002]. Although the
above evidences strongly supports the pro-tumorigenic role of HAS, the tumor
promoting ability of HAS up-regulation can not be generalized because HAS2
overexpression can e.g. also inhibit the tumorigenesis of glioma cells [Cheng
et al. 2007].
1.5.1 Tumor cell derived hyaluronan
Hyaluronan possitive cancer cells were detected in about half of the breast and
prostate tumor cases and over 80 % of ovarian, colorectal and gastric cancers
showed hyaluronan positive cancer cells [Auvinen et al. 2000; Ropponen et al.
1998; Lipponen et al. 2001; Anttila et al. 2000; Seta¨la¨ et al. 1999]. In most
cases, hyaluronan is detected arround the plasma membrane, and it also occa-
sionally exists in the cytoplasm and even in the nucleus [Auvinen et al. 2000;
Ropponen et al. 1998]. The proportion of hyaluronan-positive cancer cells, as
well as the intensity of hyaluronan staining on those cells, directly correlates with
tumor grade and degrees of cell differentiation [Auvinen et al. 2000; Ropponen
et al. 1998; Anttila et al. 2000; Seta¨la¨ et al. 1999; Hautmann et al. 2001; Pirinen
et al. 2001; Suwiwat et al. 2004]. Furthermore, cancer metastasis often derives
20
Introduction
from primary tumors with high hyaluronan expression suggesting an active role
in cancer metastasis [Anttila et al. 2000; Bo¨hm et al. 2002]. Furthermore, high
hyaluronan levels in the cancer cells associate with unfavorable outcomes, i.e.
shortened overall survival (OS) time and disease free survival (DFS) time in
breast, gastric and colorectal cancers [Auvinen et al. 2000; Ropponen et al.
1998; Seta¨la¨ et al. 1999; Ko¨bel et al. 2004]. However, other studies showed
that accumulation of hyaluronan in tumor could serve as a favorable prognostic
factor. In lung squamous cell carcinoma, de-differentiated cancer cells showed
less HA staining compared to higher differentiated ones with a more promising
prognosis [Pirinen et al. 1998]. Therefore, the role of hyaluronan and its associ-
ation with progression and metastasis can not be generalized and needs to be
studied in different cancer entities.
1.5.2 Hyaluronan in stromal tissue
Stromal hyaluronan is increased in breast tumors, and this increase was more
prominent at the invasion front than in the central tumor areas [Bertrand et al.
1992; Ponting et al. 1993]. It was later confirmed that the increased stromal
hyaluronan is not restricted to breast cancer but also present in prostate, ovar-
ian, bladder, endometrial, thyroid carcinomas and lung adenocarcinomas [Au-
vinen et al. 2000; Lipponen et al. 2001; Anttila et al. 2000; Pirinen et al. 2001;
Lokeshwar et al. 2001; Afify et al. 2005; Aaltomaa et al. 2002; Ekici et al. 2004;
Posey et al. 2003; Hiltunen et al. 2002]. Stromal HA can be markedly induced
in tissue with low basal HA level. For instance, the stromal HA increased up
to 49 fold in grade 3 ovarian cancer [Hiltunen et al. 2002]. High grade and
poorly differentiated tumors are often paralleled with intense stromal hyaluro-
nan. Furthermore, high levels of HA in stroma are also associated with cancer
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cell penetration of capsules, lymph vessels and nerves in prostate carcinomas,
local lymph node infiltration in breast cancers and with distant metastasis in thy-
roid, ovarian and prostate cancers [Auvinen et al. 2000; Lipponen et al. 2001;
Anttila et al. 2000; Bo¨hm et al. 2002; Lokeshwar et al. 2001; Aaltomaa et al.
2002; Wernicke et al. 2003]. 50 % of the breast cancer patients with high stro-
mal hyaluronan passed away during 5 years of follow up, while all patients with
low stromal hyaluronan survived [Auvinen et al. 2000]. The corresponding sur-
vival rates in ovarian cancer were 25 % and 45 % [Anttila et al. 2000]. Concisely,
tumors with intensive stromal hyaluronan are induced in proliferation and metas-
tasis.
1.6 Esophageal cancer
Esophageal cancer is the 3rd most common gastrointestinal malignancy [Blot
and McLaughlin 1999] and is the 6th most frequent cancer worldwide [Parkin
et al. 1999]. The incidence rate of esophageal cancer dramatically varies in dif-
ferent geographical regions of the world [Gore 1997]. The highest incidence of
the disease occurs in the Esophageal Cancer Belt which stretches from eastern
Turkey to Iraq, Iran, China, India, and certain regions of South Africa [Ribeiro
et al. 1996]. More than 90 % of the esophageal cancers are either squamous
cell carcinomas (ESCC) or esophageal adenocarcinomas (EAC) [Blot 1995].
Although patient presentation of ESCC and EAC are similar, the epidemiology,
etiology, prognosis and treatment strategy are quite different [Mariette et al.
2005; Siewert and Ott 2007]. ESCC and EAC are considered to represent two
different diseases occuring in the same organ.
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1.6.1 Epidemiology
Until the 1970s, ESCC was the dominent type of esophageal cancer. High
incident regions of ESCC are in the Southern and Eastern Africa and a cen-
tral Asian belt passing from Turkey through Iran, Iraq, Kazakhstan, Mongolei
and onto Northern China. The incidence in high-risk areas can reach up to
100/10,000 per year compared to 5 -10/10,000 per year in Western countries
[Holmes and Vaughan 2007]. Worldwide, the male:female ratio is 3:1. How-
ever, the distribution is more equal in the high-risk regions reflecting an equal
exposure to risk factors [Wabinga et al. 2000].
During the last 30 years, there has been a decline or stabilization in the in-
cidence of ESCC in Western contries [Keeney and Bauer 2006; Vizcaino et al.
2002; Pera 2003; Pera et al. 2005; Newnham et al. 2003a]. Over the same
period, the age-standardized incidence of EAC has risen faster than any other
malignancy in Western world. Though, EAC was a rare disease with the inci-
dence < 1:100,000 before the 1970s, the incidence of EAC has now exceeded
that of ESCC [Pohl and Welch 2005; Shaheen 2005; Lagergren 2005]. The inci-
dent rise is most significant in the white male population. It reaches 5 / 100,000
for white male in US and 8 -12 / 100,000 in the highest incident countries of
Australia and the UK [Newnham et al. 2003a; Kubo and Corley 2002, 2004;
Bollschweiler et al. 2001; Lord et al. 1998; Newnham et al. 2003b; Devesa et al.
1998; Registry 2000]. The age distribution of EAC peaks at 50 - 60 years and
the male:female ratio is between 2:1 and 12:1 [Botterweck et al. 2000].
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1.6.2 Etiology
ESCC is associated with many environmental factors including diet rich in pre-
served or pickled food, lack of fresh fruit and vegetables, vitamin and mineral
deficiencies, and a thermal effect of hot food and beverages. Alcohol intake and
smoking are also strong risk factors for ESCC [Farhadi et al. 2005; Bahmanyar
and Ye 2006; Boeing et al. 2006]. Ethnic, obesity, esophageal sphincter-relaxing
drugs, smoking and alcohol consumption have all been convicted as etiological
factors in EAC [DeMeester and DeMeester 2000; DeMeester 2006; Lagergren
et al. 2000; Lagergren and Jansson 2006; Lagergren et al. 1999a]. Cohort stud-
ies showed that gastroesophageal reflux and Barrett’s disease represent causal
factors for EAC [Solaymani-Dodaran et al. 2004; Lagergren et al. 1999b].
1.6.3 Prognosis
The prognosis of ESCC and EAC is poor and the overall tumor-specific lethality
rate reaches up to 95 % [Lagarde et al. 2006]. Female appears to have better
outcomes than male. The 5-year survival rate ranges from 5 % to 20 % for the
patients undergoing operations with curative intent. Tumors in the upper esoph-
agus associated with high operative risks. The immediate surgical results are
consistently worse for ESCC than for EAC [Siewert and Ott 2007; Alexandrou
et al. 2002; Abunasra et al. 2005]. This might be due to the fact that ESCC often
existed in the mid or upper esophagus and is associated with other comorbidi-
ties such as age, chronic respiratory disease, liver disease and poor nutrition.
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Aim of Study
Aim of Study
H Yaluronan plays an important role in modulating cell phenotypes such ascell motility, cell-cell and cell-matrix adhesion, cell proliferation and differ-
entiation. Elevated hyaluronan levels in the cancer epithelium and peritumoral
stroma are thought to promote tumor progression.
HAS isoforms, HAS1, HAS2 and HAS3v1, are shown to be transmembrane
proteins and in charge of extracellular HA synthesis. HAS3v2 is a smaller splic-
ing variant of HAS3 that has been described in cultured human keratinocytes
but has not been studied with respect to function yet.
Therefore, the following questions were addressed in this Ph.D thesis:
• What is the subcellular localization of HAS3v2 in comparison to HAS3v1?
• Does HAS3v2 have enzymatic activity?
• Does HAS3v2 expression alter the cellular phenotype of cancer cells in
vitro and in vivo?
• Is HAS3v2 expressed in human esophageal cancer patients?
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Material and Methods
Material and Methods
3.1 Materials
4-Methylumbelliferone Sigma-Aldrich, Munich
Acrylamide 40 % BioRad, Munich
Ammonium persulfate (APS) BioRad, Munich
DMEM cell culture medium Gibco-Invitrogen, Karlsruhe
Hoechst 33324 Sigma-Aldrich, Munich
Image-iT LIVE Plasma Membrane marker Invitrogen, Karlsruhe
ER Tracker red Invitrogen, Karlsruhe
EndoFree Plamid Maxi Kit Qiagen, Hilden
PageRule Prestained Protein Ladder Fermentas, St.leon-Rot
Poly-L-Lysine Sigma-Aldrich, Munich
Pronase Sigma-Aldrich, Munich
Protaminsulfate Sigma-Aldrich, Munich
RPMI 1640 cell culture medium Sigma-Aldrich, Munich
Streptomyces Hyaluronidase Sigma-Aldrich, Munich
Quantitect reverse transcription Kit Qiagen, Hilden
CyQUANT NF Cell Proliferation Assay Kit Invitrogen, Karlsruhe
Platimium SYBR Green qPCR supermix -UDG w/ROX Invitrogen, Karlsruhe
Tri-Reagent Sigma-Aldrich, Munich
Vectashield Antifade Mounting Medium Vector Laboratories, CA, USA
Vitrogen 100 Collagen Corp, Palo Alto, CA.USA
Whatman-Paper Schleichter und Schuell, Maidstone,England
PVDF-Membrane Bio-Rad Laboratories, Hercules, CA, USA
Table 3.1: Chemicals and Kits
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Electrophoresis cham-
ber (Protein)
Mini-PROTEAN3 Elec-
trophoresis cell, Power-
Pac 200 +300 Power
Supply
BioRad, Munich
Fluorescent-
Microscope incl.
Camera and Software
Epifluorescent inverse
microscope Axiovert
100
Zeiss, Oberkochen
Confocal Microscope Zeiss LSM510 Zeiss, Oberkochen
Microscope Leica Upright Micro-
scope
Leica, Wetzlar
Protein-Transfer
(Western-Blot
PerfectBlue Semi-Dry
Elektroblotter
Prqlab, Erlangen
RNA, DNA quantifica-
tion
Nanodrop-1000 Reqlab, Erlangen
Microplate reader (UV) Multiskan Ascent Thermo Fischer, Dreieich
Microplate reader (Flu-
orescence)
Fluoroskan Ascent Thermo Fischer, Dreieich
PCR-Machine Mastercycler Gradient Eppendorf, Hamburg
Realtime-PCR-
Machine
Applied Biosystems
7300 Real-Time PCR
System
Applied Biosystems, Darm-
stadt
Centrifuge Centrifuge 5415R Eppendorf, Hamburg
Immunoblot imager Odyssey Infrared Imag-
ing System
Licor, Bad Homburg
Table 3.2: Equipments
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1 × Running Buffer
250 mM Tris (Trishydromethylaminomethane)
1.9 mM Glycine
0.1 % SDS
1 × Protein Lysis Buffer
1 % SDS
1 mM PMSF (Phenylmethysulfonylfluoride)
10 mM Tris pH 7.4
2 × Loading Buffer
125 mM Tris pH 6.8
4 % SDS
10 % Glycerol
Stacking gel (5 %)
0.5 M Tris pH 6.8 0.625 ml
10 % SDS 50 µl
dH2O 3.895 ml
40 % Acrylamide 375 µl
Temed 5 µl
APS 10 %-0.1 g/ml 50 µl
Separating gel (10 %)
3 M Tris pH 8.7 0.975 ml
10 % SDS 75 µl
dH2O 4.545 ml
40 % Acrylamide 375 µl
Temed 5 µl
APS 10 %-0.1 g/ml 25 µl
Blocking Buffer 2 % (w/v) BSA in 1 × TBST
1 × Transfer-Buffer
1 × Running Buffer
20 % Methanol
0.01% SDS
10 × TBS
100 mM Tris / HCI
1.5 mM NaCI
pH7.4
1 × TBST
1 × TBS
0.1 Tween 20
Table 3.3: Recipe of Immunoblot
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Human specific primers (5’ - 3’) Murine specific primers (5’ - 3’)
HAS1 F TACAACCAGAAGTTCCTGGG CTATGCTACCAAGTATACCTCG
HAS1 R CTGGAGGTGTACTTGGTAGC TCTCGGAAGTAAGATTTGGAC
HAS2 F GTGGATTATGTACAGGTTTGTGA GAGATGGTGAAGGTCTTAGAG
HAS2 R TCCAACCATGGGATCTTCTT AAAGCCATCCAGTATCTCAC
HAS3v1 F GAGATGTCCAGATCCTCAACAA CTCAGTGGACTACATCCAGG
HAS3v1 R CCCACTAATACACTGCACAC GACATCTCCTCCAACACCTC
HYAL1 F CTTCTATGACACGACAAACCA GAAATGACAGATTATCTTCTGCCC
HYAL1 R ATACTCCTTGATGGCCTGAC TTGTCTGAGCTTAGCCAGAG
HYAL2 F CTCATCTCTACCATTGGCGA GCTTCAAGTATGGAGACCTG
HYAL2 R GTGTCAGGTAATCTTTGAGGT GGACACGTTGACTATGTAGG
CD44s F CTGCTACCAGAGACCAAGAC AGGATGACTCCTTCTTTATCCG
CD44s R TCCATCTGATTCAGATCCATGAG CTTGAGTGTCCAGCTAATTCG
RHAMM F AACACTTTGATCCTTCAAAGGC GAATATGAGAGCTCTAAGCCTG
RHAMM R ATTCTTGACACTCCATAGGAGC CCATCATACTCCTCATCTTTGTC
GAPDH F CATTTCCTGGTATGACAACGA GCTCATTTCCTGGTATGACAAT
GAPDH R TCTCTTCCTCTTGTGCTCTTG TCTCTTGCTCAGTGTCCTTG
HAS3v2 F ATTCGGTGGACTACATCCAG
HAS3v2 R CTACTGCCATACCTTTCCCT
Table 3.4: Species specific primers for RT-qPCR
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3.2 E. coli
3.2.1 E. coli strains
The following strains of E.c oli were used for cloning and plasmid amplification.
XL1-Blue: endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F’[ ::Tn10 proAB+
lacIq ∆(lacZ)M15] hsdR17(rK− mK+)
DH-5α: F− endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG φ80dlacZ∆M15
∆(lacZYA-argF )U169, hsdR17(rK− mK+), λ-
3.2.2 Generation of competent E. coli cells
E. coli were grown in 1 liter SOB medium at 37 ◦C and harvested (4000 × g, 20
min, 4 ◦C), when the OD 600 value of the culture reached 0.5 - 0.8. Cells were
gently resuspended in 40 ml ice-cold TB buffer (10 mM Pipes, 55 mM MnCl2,
15 mM CaCl2, 250 mM KCl), incubated on ice for 20 min and again sedimented
(4000 × g, 20 min, 4 ◦C). Cells were gently resuspended in 20 ml ice-cold
TB buffer and DMSO was added with gentle swirling to a final concentration of
7 %. After 10 min incubation on ice, cells were dispensed in 0.1 ml aliquots,
chill-frozen in liquid nitrogen and stored at -80 ◦C.
3.2.3 Transformation of E. coli
An aliquot of 0.1 ml competent cells was mixed with 2 µl ligation reaction mix-
ture, incubated on ice for approximately 30 min, shocked at 42 ◦C 30” and im-
mediately transfered onto the ice. Then, 0.5 ml warm LB-medium (37 ◦C)was
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added to the cells and the mixture was incubated for 1 h at 37 ◦C with vigorous
shaking (250 rpm). Afterwards, transformed cells were transferred to LB-agar
plates containing 50 µg/ml ampicillin.
3.2.4 Plasmid preparation
Colonies were picked and inoculated in 2.5 ml TB medium containing 50 µg/ml
ampicillin and incubated overnight at 37 ◦C with vigorous shaking (250 rpm).
After approximately 14 hours, 2 ml of the culture were pelleted (6800 × g, 2
min, 4 ◦C). The cell pellet was mixed with 400 µl lysis solution (0.2 N NaOH,
1 % SDS), immediately neutralized with 300 µl 7.5 M NH4OAC and kept for 10
min on ice, to precipitate genomic DNA and proteins, then sedimented at 14000
× g for 10 min at 4 ◦C. The plasmid DNA was precipitated from the supernatant
with 500 µl 2-propanol and pelleted (14000 × g, 30 min, 4 ◦C). Finally, the DNA
pellet was washed with 70 % EtOH, dried and resuspended in 50 µl TE (10 mM
Tris-HCl pH 8.0, 1 mM EDTA) supplemented with 50 µg/ml RNaseA.
For Maxiprep, a single colony was picked and inoculated in a primary culture
of 3 ml TB medium (containing selection reagent accordingly) and incubated for
approx. 8 h at 37 ◦C with vigorous shaking (250 rpm). Afterwards the initial cul-
ture was diluted 1:1000 into 250 ml selective TB medium and grown overnight.
Bacterial cells were harvested by centrifugation (6000 × g, 15 min, 4◦C) and
the purification of plasmid DNA was performed with QIAGEN Endofree Plasmid
Maxi Kit according to manufacturer’s protocol. DNA concentration was deter-
mined spectrophotometricly by absorption at the wavelength of 260 nm.
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3.3 Cell culture
PT1590 cells, skin fibroblasts and HEK cells were kindly provided by Dr. Stoeck-
lein, Dr. Reifenberger and Dr. Mielke, respectively. PT1590 cells were grown in
RPMI 1640 medium (Invitrogen, Karlsruhe) containing 10 % fetal bovine serum
(Invitrogen, Karlsruhe) and 1 % penicillin/Streptomyces (Invitrogen, Karlsruhe).
HEK cells and skin fibroblasts were grown in DMEM medium (Invitrogen, Karl-
sruhe) supplied with 10 % fetal bovine serum and 1 % penicillin/Streptomycin
solution. Culture medium for stable transfected HEK cells was supplemented
with puromycin (Invitrogen, Karlsruhe) at 0.4 µg/ml to maintain selection pres-
sure. PT1590 and HEK cells were maintained as subconfluent monolayer cul-
tures at 37 ◦C under a humidified 5 % CO2 atmosphere. For passaging, cell
layers were washed once with PBS (Invitrogen, Karlsruhe), detached by a short
trypsinization with Trypsin- EDTA solution (0.5 g/L of trypsin (1:250) and 0.2 g/L
of EDTA·4Na) and reseeded with the density of 5000 cells/cm2 for skin fibrob-
lasts and 2000 cells/cm2 for PT1590 and HEK cells, accordingly.
3.4 RNA isolation and cDNA reverse transcription
Total RNA from cultured cells and tissues was isolated using either the RNeasy
mini kit (Qiagen, Hilden) or TriReagent (Sigma-Alderich, Muenchen). Before
RNA isolation, the tumors from the xenograft model were homogenized by the
Mixer Mill MM 200 (Retsch, Haan). The RNA concentration was determined by
photometric measurement at 260 nm using Nanodrop-1000 (Peqlab, Erlangen).
Aliquots of total RNA (1 µg) were applied for cDNA synthesis using Quantitect
reverse transcription kit (Qiagen, Hilden). These experiments were performed
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according to the manufactures’ protocols.
3.5 Realtime RT quantitative PCR (qPCR)
Relative mRNA expression levels were quantified by qPCR. PCR was performed
using an ABI 7300 real time system (Applied Biosystems, Darmstadt) with Plat-
inum SYBR green qPCR SuperMix-UDG kit (Invitrogen, Karlsruhe). The re-
action mixture for each gene contained 10 µl of Platinum SYBR green qPCR
SuperMix-UDG, 5 µl cDNA and 2.5 µl of each primer (with final concentration
of 10 pmol) in a final volume of 20 µl. Glyceraldehyde- 3-phosphate dehydroge-
nase (GAPDH) was chosen as the endogenous control using the same reaction
mixture and conditions. All PCR primer sequences were designed by Primer3
software (http://frodo.wi.mit.edu/primer3/) (listed in section 3.1). The PCR am-
plification condition was as the following: 50 ◦C for 2 min and 95 ◦C for 2min, and
this was followed by 40 cycles at 95 ◦C for 30 s and then 60 ◦C for 30 s. During
the last steps, a temperature gradient between 95 ◦C and 60 ◦C was created for
the analysis of the dissociation curves. This post-PCR dissociation curve was
used to monitor the quality of PCR. No template controls, substituting water for
cDNA, and a negative reverse transcription were used in each run. Target gene
expression was calculated for each sample relative to the housekeeping gene,
GAPDH, using the 2−∆∆Ct method as described [Dai et al. 2007].
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3.6 Quantification of HA from extra-, peri-and in-
tracellular compartments
HA from the extracellular, pericellular and intracellular compartments of cul-
tured cells were isolated and quantified as previously described [Wilkinson et al.
2006]. 24 hours after changing medium, culture supernatant was harvested and
used for determination of extracellular HA. Next, cells were gently washed in
PBS, trypsinized and centrifuged at 1000 × g for 5 min. The resulting super-
natant was taken and HA determined in this fraction was defined as pericellular
HA. Afterwards, the cell pellet was washed twice in PBS and centrifuged at 1000
× g for 5 min. Aliquots from the cell pellets were collected to isolate total pro-
tein. The protein concentration, which mimics the total cell number, was then
quantified by Bradford protein assay (Bio-rad, Mu¨nchen) and used to normalize
the HA concentration. The HA from the cell pellet represented the intracellular
HA fraction. The culture medium, the trypsin supernatant and the cell lysate
were then digested by papain (5 mg/ml) in 0.1 M Tris-acetate, 5 mM EDTA, 5
mM L-cysteine hydrochloride at pH 7.3 for 24 hours at 60 ◦C. After digestion,
papain was then inactivated by heating to 100 ◦C for 20 min. The HA concentra-
tion was subsequently measured by a commercial HA ELISA test kit (Corgenix,
Peterborough).
3.7 Cell proliferation
CyQUANT NF cell proliferation kit was used to measure the growth rate of
PT1590 cells according to the manufacture’s protocol. Briefly, PT1590 cells
were seeded in a 96 well microplate at a density of 4000 cells per well. For
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each condition, the cells were seeded as octuplicate. The CyQUANT NF dye
reagent was diluted 1:500 in 1× HBSS buffer (Hank’s buffered salt solution in-
cluded in the kit). For the measurement, the culture medium was removed and
100 µl 1× dye reagent was dispensed to each microplate well. Instead of the
dye reagent, 100 µl 1× HBSS buffer was used as the background count. The
microplate was then incubated at 37 ◦C for 30 min. Fluorescence intensity of
each sample was measured using a fluorescence microplate reader (excitation
at 485 nm and emission at 530 nm). The cells were first allowed to adhere for 4
hours. The control value was therefore taken after 4 hours adhesion. 24 hours
after seeded, the cell density was again measured and the proliferation rate was
calculated with normalization to the 4-hour initial value.
3.8 Cell adhesion
PT1590 cells were trypsinized and washed two times with PBS before assessing
the adhesion. The cells were resuspended to 1 × 106 cells/ml with culture
medium containing 10 % FCS. Subsequently, the cells were seeded in 96-well
plates (100 µl per well). After 15 minutes of incubation at 37 ◦C, the unattached
cells were washed away by PBS buffer. The attached cells were then fixed and
stained by crystal violet solution containing 50 % methanol for 5 min at 22 ◦C
and washed 6 times with 100 µl ddH2O. Finally, the cells were lysed by 100
µl 2 % SDS. A UV spectrometric microplate reader was used to determine the
absorption at 540 nm.
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3.9 Cell growth kinetics
After trypsinazation, cells were resuspended and seeded in 12-well plates at a
density of 4000 cells per well. The cell number was determined by a Neubauer
chamber at 1, 2, 3, 4, and 5 days after seeding. Before loading onto the
Neubauer chamber, the cell suspension was mixed 1:1 with trypan blue to dis-
tinguish living and dead cells.
3.10 Intracellular HA staining & confocal imaging
Staining of intracellular hyaluronan was performed as previously described us-
ing a biotinylated hyaluronan-binding protein specific for hyaluronan [Evanko
and Wight 1999]. Skin fibroblasts (2 × 105 per 6-well) were plated and grown
on 22-mm2 coverslips inserted into the wells for 24 hours in DMEM containing
10 % fetal bovine serum. Extracellular and pericellular hyaluronan was removed
prior to fixation by incubating the cells with 2 U/ml Streptomyces hyaluronidase
(Sigma-Aldrich, Mu¨nchen) in culture medium at 37 ◦C for 60 min. Cells were
fixed in 3.7 % paraformaldehyde in PBS for 10 min at 22 ◦C and then permeabi-
lized with 0.5 % Triton X-100 for 10 min. Afterwards, cells were blocked with 1 %
BSA in PBS for 1 hour at 22 ◦C. The biotinylated HABP was used at a concentra-
tion of 2.5 µg/ml in PBS containing 1 % BSA for 1 hour at 22 ◦C. The biotinylated
HABP was further detected with Cy3-streptavidin. Nuclei were counterstained
with Hoechst 33342 (Invitrogen, Karlsruhe) at 1 µg/ml in H2O for 10 min at 22
◦C. Coverslips were mounted with Antifade Mounting Medium (Vector Labora-
tories, CA, USA). Controls for specificity of the intracellular hyaluronan staining
included digestion of the cells with Streptomyces hyaluronidase after permeabi-
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lization and without permeabilization before adding biotinylated HABP.
For microscopic analysis, a Zeiss inverted LSM 510 META confocal laser
fluorescent microscope (Carl Zeiss, Jena) with 63 ×/1.4 NA oil-immersion ob-
jective was used. Hoechst 33342 was excited by diode laser at 351 nm. Argon
laser was used to excite Cy3 at 543 nm wavelength. The emission signals were
collected through proper filters. All the images, including the negative controls,
were taken under the same condition.
3.11 Vector construction of stable transfection
The pMC-EYFP-P vector was used for YFP-HAS fusion protein construction.
As shown in figure 3.1, the CMV promoter drives the expression of YFP fusion
protein as well as the selection marker, namely puromycin resistant gene (pAC).
Human HAS2, HAS3v1 and HAS3v2 coding sequences were isolated from total
RNA of human smooth muscle cells by RT-PCR with primers indicated in ta-
ble 3.5. The PCR products of HAS2 and HAS3v1 are about 1.7 kb and HAS3v2
about 0.9 kb respectively. The multicloning site is located at the c-terminal of the
YFP coding sequence. N-terminal YFP-HAS fusion protein coding sequences
were constructed using the MluI and EcoRI restriction sites. All the coding se-
quences were controlled by sequencing.
3.12 Construction of stably transfected cell lines
HEK cells were grown until they reach 80 % confluency in monolayer culture
(25 cm2). Then, HEK cells were splitted 1:4 24 hours before transfection. Cells
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Figure 3.1: Vector map of pMC-EYFP-P
CMV promoter drives the expression of YFP fusion protein as well as the selection marker,
namely puromycin resistant gene (pAC). The multicloning site is located at the c-terminal of the
YFP coding sequence. Human HAS2, HAS3v1 and HAS3v2 coding sequences were isolated
from total RNA of human smooth muscle cells by RT-PCR. N-terminal YFP-HAS fusion protein
coding sequences were constructed using the MluI and EcoRI restriction sites.
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Primer sequences (5’ - 3’)
MluI-hHAS2-F AAAACGCGTATGCATTGTGAGAGGTTTCT
EcoRI-hHAS2-R AAAGAATTCTCATACATCAAGCACCATGT
MluI-hHAS3v1-F AAAACGCGTATGCCGGTGCAGCTGACGACAG
EcoRI-hHAS3v1-R AAAGAATTCTCACACCTCAGCAAAAGCCAAG
MluI-hHAS3v2-F AAAACGCGTATGCCGGTGCAGCTGACGACAG
EcoRI-hHAS3v2-R AAAGAATTCTCACTGCTCTCTAGAAACGTGG
Table 3.5: Primers for YFP-HAS fusion protein construction
were transfected with 1 µg DNA using Effectene Transfection Reagent (Qiagen,
Hilden) according to the manufacturer’s instructions. Transfection efficiency was
monitored by fluorescence microscopy after 24 hours. The transfection effi-
ciency appeared to be between 20 - 90 % depending on the construct used.
30 hours after transfection, cells were appropriately seeded into d-150 (150 mm
in diameter) tissue culture dishes. Subsequently, stably transfected cell clones
were selected by 0.4 µg/ml puromycin for 7 days. Stably expressing clones were
then picked and reseeded in the 6-well in selection medium. For maintenance,
the stable cell clones were cultured in selection medium.
3.13 Live-cell staining and imaging
The live-cell-imaging chamber (Ibidi, Martinsried) was coated with 200 µl poly-
L-lysine (25 µg/ml) for 2 hours at 22 ◦C under sterile condition. 24 hours before
microscopy, the HEK cells were seeded in a live-cell-imaging chamber at a den-
sity of 5000 cells/cm2. Before microscopy, the culture medium was exchanged
by CO2-independent medium (Invitrogen, Karlsruhe). An epifluorescent micro-
scope and a 40 × oil immersion objective were used for imaging. The objective
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holder was pre-warmed to 37 ◦C before usage.
To study subcellular localization, cells were stained with either Image-iT LIVE
plasma membrane labeling Kit (Invitrogen, Karlsruhe) or ER-Tracker Red (Invit-
rogen, Karsruhe) according to the manufacturer’s protocol.
3.14 HAS enzymatic capture assay
Enzymatic activity of cellular HAS isoforms was determined in microsomal prepa-
rations. Briefly, cells were sonicated in microsome buffer (PBS containing 0.01
% SDS, 1 mM PMSF, 1mM EDTA, 20 mM DTT) for 12 min and were vortexed in
between. The plasma membrane and nuclear fragments were then sedimented
by centrifugation at 10,000 × g at 22 ◦C for 20 min. Supernatants were col-
lected for additional centrifugation at 100,000 × g for 1 hour at 4 ◦C. The pellet,
which is enriched in microsomes, was resolved in 200 µl microsome G buffer
(PBS containing 0.01 % SDS, 1 mM PMSF, 1 mM EDTA, 20 mM DTT with 30
% Glycerol) and stored at -20 ◦C for overnight. Microsomes were mixed 1:1
with HAS buffer (PBS containing 2 mM MgCl2, 1 mM UDP-Glucosamine, 1mM
UDP-Glucuronic acid, 1 mM PMSF, 1 mM EDTA, 1 mM DTT ) and incubated at
37 ◦C for 24 hours. As control, half of the microsomal solution was treated with
Streptomyces hyaluronidase for 2 hours at 37 ◦C to remove the HA from the
HA-HAS complex. Subsequently, 1 µg of biotinylated HABP was added to the
microsomes with/without Streptomyces hyaluronidase treatment and incubated
at 37 ◦C for 1 hour. Strepavidin-agarose beads were added to each vial and
incubated at 22 ◦C for 1 hour. The agarose beads were pelleted by centrifuga-
tion and washed two times with PBS. Then, protein lysis buffer (receipt shown
in section 3.15.1) was added to the agarose beads to elute proteins from the
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beads. The protein lysate was collected by centrifugation and denatured for 5
min at 95 ◦C prior to further analysis.
Microsomal preparations from YFP, YFP-HAS3v1 and YFP-HAS3v2 stably
trasfected HEK cells were used for HAS enzymatic activity assay. Protein lysates
were run on 10 % SDS-PAGE gels according to routine procedures. After blot-
ting, the nutrocellulose membranes were blocked by blocking buffer (recipe in
section 3.1) at 22 ◦C for 1 hour. Then, the membranes were incubated with the
YFP antibody (Clontech, France) dilluted 1:4000 in blocking buffer with gentle
agitation overnight. Membranes were washes three times with 1 × TBST for 5
minutes each and further incubated with IRDye 800CW Goat Anti-Mouse IgG
(Licor, Bad Homburg) with 1:5000 dilution in blocking buffer at 22 ◦C for 1 hour.
Finally, membranes were washed 6 times with 1 × TBST for 5 minutes each
and images were taken and analyzed by Odyssie Imager (Licor, Bad Homburg).
3.15 Immunoblotting
Recipes of buffers and gels used for immunoblotting are listed in section 3.1
3.15.1 Protein isolation from cultured cell
Cell lysis was performed with lysis buffer (100 mM Tris-HCl, pH 6.8, 2 % Glyc-
erol, 2 % SDS, 10 mM DTT, 0.7 M Urea, 10 mM EDTA, 1 mM PMSF, 0.02 %
bromphenol blue). Cell lysates were homogenized by sonification for 15 min.
Subsequently, samples were denatured at 95 ◦C for 5 min. Protein sample were
then stored at -20 ◦C.
43
Material and Methods
3.15.2 SDS-Polyacrylamide Gel Electrophoresis (PAGE) & Coomassie
staining
Protein lysates were run on 10 % SDS-PAGE gels according to routine proce-
dures.
The SDS gel was stained by Pageblue protein stain solution (Fermentas,
St. Leon-Roth) according to the manufacturer’s protocol. Briefly, the gel was
washed 3 times with 100 ml ddH2O for 10 min each to wash SDS away. Then,
the gel was soaked in the pageblue protein stain solution for 1 hour with gentle
agitation. To remove the background staining, the gel was rinsed with ddH2O
for 5 min before imaging.
3.15.3 Blotting
Proteins were electrophoretically transferred from the gel to nitrocellulose mem-
branes by the semi-dry method. Briefly, 3 Whatman papers were soaked in
transfer buffer and then stacked on the cathode side of the gel. Then, the ni-
trocellulose membrane was shortly rinsed in the transfer buffer and carefully
stacked on the anode side of the gel. Another 3 Whatman paper were stacked
on top of the membrane after soaking in transfer buffer. Subsequently, the stack
was placed between two graphite plates and the trans-membrane blotting was
performed with constant volt 12 V for 1 hour.
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Antibody Company Dilution Ratio
YFP (JL8) Clontech 1:4000
β-Tubulin Santa Cruz 1:10000
FAK BD Bioscience 1:1000
phospho-FAK Cell Signaling 1:1000
ERK Cell Signaling 1:1000
phospho-ERK Cell Signaling 1:1000
IRDye 800CW Goat Anti-Mouse IgG Licor 1:5000
IRDye 680 Goat Anti-Rabbit IgG Licor 1:5000
Table 3.6: Antibody dilution ratios
3.15.4 Immunodetection of protein
The nitrocellulose membrane was blocked in blocking buffer with gentle agitation
for 1 hour at 22 ◦C. Afterwards, the first antibody was diluted in blocking buffer.
The membrane was incubated in the first antibody solution on the shaker for
either 1 hour at 22 ◦C or overnight at 4 ◦C. Then, the membrane was washed
three times in 1× TBS containing 0.1 % Tween 20 for 5 min each. After washing,
the membrane was soaked for 1 hour at 22 ◦C with the secondary antibody. The
secondary antibody was diluted with blocking buffer under corresponding ratio.
The antibody dilution ratios are listed in table 3.6. The blot membrane was then
immersed 5 times for je 3 min in 1 ×TBS containing 0.1 % Tween 20. Finally,
the image was taken and analyzed by Odyssiey Imager (Licor, Bad Homburg).
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3.16 Lentiviral transduction
3.16.1 Overexpression vector cloning
Lentiviral vectors can deliver large cDNAs to a variety of dividing and non-
dividing cells, including terminally differentiated mammalian cells e.g. neurons,
lymphocytes and macrophages. Due to the lack of toxicity and immune re-
sponse, lentiviruses became a very attractive tool for gene delivery and possibly
further use for human gene therapy. The safety of the lentiviral vectors has been
improved with the generation of self-inactivating vectors and a minimal packag-
ing system. For this study, a vector system constructed by Prof. Hanenberg
was used [Dai et al. 2007]. The HIV envelope glycoprotein was replaced by
VSV-G. To minimize the amount of HIV coding regions present in the packag-
ing system, a second generation of the packaging system was develolped with
extensive deletions of the viral genome. This 2nd generation packaging system
contains only the gag, pol, tat, and rev genes of HIV-1 and lacking all acces-
sory genes, since accessory genes (vpr, vpu, vif and nef) are not required for
efficient production of viral particles. The 2nd generation lentivirus packaging
system contains 3 plasmids. The pVSVG is the plasmid that encodes the enve-
lope protein. pCD/NL-BH is the packaging plasmid and pCL1 was used as the
transfer plasmid. The pCL1 is used as the mock vector, which is characterized
by the EGFP expression (shown in figure 3.2). pCL1mcs was digested by re-
striction enzyme XhoI and EcoRI. The cDNA of human HAS3v2 was obtained
by RT-PCR using total RNA from human smooth muscle cells with the follow-
ing primers: XhoI-HAS3v2-F: AAACTCGAGATGCCGGTGCAGCTGACGACAG
and EcoRI-HAS3v2-R: AAAGAATTCTCACTGCTCTCTAGAAACGTGG. Then,
the human HAS3v2 cDNA was cloned into the multiple cloning site of pCL1mcs
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to achieve the new plasmid named pCL1mcs-HAS3v2. The coding sequence of
HAS3v2 in the pCL1mcs-HAS3v2 was confirmed by sequencing.
3.16.2 Lentivirus production
The day before transfection, HEK293T cells were seeded into d-100 (100 mm
in diameter) cell culture dishes at a density of 2.5 - 3 × 106 cells per plate.
DMEM medium supplied with 10 % heat-inactivated FCS (v/v) (PAN biotech,
Aidenbach) and 1 × penicillin/Streptomycin (100 U/ml of penicillin, 100 µg/ml of
Streptomycin) was used for virus production.
Transfection was carried out using polyethylenimine (PEI) (Sigma-Aldrich,
Mu¨nchen) method. 5 µg of transfer vector, either pCL1 mock or HAS3v2 over-
expression vector pCL1mcs-HAS3v2, 5 µg of packaging plasmid (pCD/NL-BH)
and 5 µg of envelope plasmid (pVSVG) were diluted with DMEM medium to a
final volume of 2 ml in a sterile reaction tube. 45 µl of 1 mg/ml PEI was added
to the vector mix, and then thoroughly vortexed. Afterwards, the mixture was
incubated for 20 min at 22 ◦C under sterile condition to allow the DNA-PEI com-
plex form. The 293T culture medium was replaced with 4 ml DMEM with 10 %
heat-inactivated FCS and 1 × Pen/Strep solution. Subsequently, the DNA-PEI
complex was added drop-wise to the 293T. After gentle mixing, the 293T cells
were incubated for 16 hours in the humidified incubator at 37 ◦C and 5 % CO2.
Then, the transfection medium was changed to complete medium containing 10
mM sodium butyrate to induce the CMV promotor activity. 6 hours after induc-
tion, the culture medium was refreshed with 5 ml IMDM medium (Sigma-Aldrich,
Muenchen) supplied with 10 % heat-inactivated FCS and 1 × Pen/Strep solu-
tion. The virus containing IMDM medium was harvested and filtered through
a 0.45 µm sterile filter 24 hours after induction. Then, the medium was either
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Figure 3.2: Vector map of pCL1mcs
The multicloning site is located after SFFV U3 fragment. Human HAS3v2 coding sequences
was isolated from total RNA of human smooth muscle cells by RT-PCR and constructed using
the XhoI and EcoRI restriction sites. CMV promoter drives the expression of either EGFP (mock
control) or HAS3v2.
48
Material and Methods
used for transduction directly or stored at -80 ◦C after aliquots.
3.16.3 Lentivirus titration
The RETRO-TEK HIV-1 p24 Antigen ELISA (Zeptometrix , USA) is an enzyme
linked immunoassay used to detect Human Immunodeficiency Virus Type 1
(HIV-1) p24 antigen. Microwells are coated with a monoclonal antibody specific
for the p24 gag gene product of HIV-1. Viral antigen in the specimen specifically
bound to the immobilized antibody during incubation. The captured antigen then
detected with a high-titer human anti-HIV-1 antibody conjugated with biotin. Fol-
lowing a subsequent incubation with Streptavidin-Peroxidase, color develops as
the bound enzyme reacts with the substrate. Resultant optical density is pro-
portional to the amount of HIV-1 p24 antigen present in the specimen.
3.16.4 Lentiviral transduction
Both skin fibroblasts and PT1590 cells were grown 50 % - 70 % confluence
before lentiviral transduction. DMEM medium was used for skin fibroblast while
PT1590 cells were transduced in RPMI 1640 medium. Both medium were sup-
plied with 10 % heat-inactivated FCS and 1 × Pen/Strep solution. For trans-
duction, equal titers of virus were thawed on ice and diluted in the appropriated
medium with 4 µg/ml protamine sulfate. Protamine sulfate is a small, positively
charged molecule that binds to cell surfaces, neutralizes surface charge and
thereby greatly enhances transduction by lentiviruses. The cell culture medium
was changed 24 hours and 96 hours after transduction.
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3.17 Xenograft of EAC cells in nude mice
3.17.1 Tumor inoculation
10 weeks-old NMRI nu/nu mice were used for subcutaneous tumor formation
after xenografting of PT1590 cells. Five days after lentiviral transduction, cell
injections were performed with 100 µl cell suspension containing 1 × 106 cells.
Cells were harvested, counted and washed two times using PBS. Then, the pel-
lets were resuspended in PBS. After cleaning the skin with alcohol, tumor cell
suspensions were injected s.c. using an 1 ml insulin syringe into both flanks,
and the mice were monitored for 35 days after xenografting. The animal exper-
iments were approved by the local animal facility and the Landesamt fr Natur,
Umwelt und Verbraucherschutz, NRW.
3.17.2 Growth curve
Starting at 14 days after injection, tumor diameters were measured with digital
calipers every 3 or 4 days. The tumor volume in mm3 was calculated by the
formula: V olume = (Length × width × height) × pi/2. The tumor growth was
monitored by determining of the cumulative tumor volume until harvesting. The
wet weight of tumors were measured at harvesting.
3.17.3 Immunohistochemistry
The mice were sacrificed by asphyxiation with CO2 and the tumors were dis-
sected. Part of the tumors were embedded in OCT Tissue Tek (Sakura Finetek,
Netherlands), frozen at -40 ◦C isopentane and stored at -80 ◦C. Cryostat CM
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3050 from Leica Instruments was used to cut 2 µm thick cryosections. Sections
were loaded on Superfrost slides (Fisher Scientific, USA) and stored at -20 ◦C.
For immunohistrochemistry, the cryo-sections were blocked with 10 % fe-
tal calf serum and 1 % bovine serum albumin for 1 hour at room temperature.
For hyaluronan staining, the slides were subsequently incubated with biotiny-
lated HAbP (2 µg/ml; Seikagaku, Tokyo, Japan) at 4 ◦C overnight. After three
washes with phosphate-buffered saline (PBS), the sections were incubated with
avidin-biotin peroxidase (Sigma, St. Louis, MO), and the color was developed
with 3,3’-diaminobenzidine (DAB; Sigma). Nuclei were stained with hemalaun
solution (Merck, Darmstadt, Germany). As a negative control, sections were in-
cubated with Streptomyces hyaluronidase (ICN, Costa Mesa, CA) at a concen-
tration of 2 U/ml (1 hour, 37 ◦C) before HA staining. Proliferation marker, Ki67,
was stained using rabbit anti- human/mouse ki67 antibody (1:25; Novus Bio-
logicals, Littleton, CO) and sheep anti-rabbit IgG (peroxidase-conjugate, 1:50;
Sigma-Aldrich, Steinheim, Germany). DAB detection was as as described for
HA staining
The images were taken at 100 × magnification with a Leica Upright Micro-
scope (Leica, Wetzlar).
3.18 Statistical analysis
Quantitative results are presented as mean values± standard error of the mean
(SEM). Data sets were compared either by unpaired T-test or one way ANOWA
using the software PRISM Graphad 5.0. p value < 0.05 was regarded as statis-
tically significant.
51
Chapter 4
Results
Results
4.1 In silico enzymatic activity analysis of HAS3v2
4.1.1 Human HAS3 splicing variants: HAS3v1 & HAS3v2.
T Here are three mammalian hyaluronan synthase isoforms, namely HAS1,HAS2 and HAS3. The structures of these three genes are evolutionary
conserved in mammalian species. Human HAS3 has two splicing variants:
HAS3v1 and HAS3v2. As shown in figure 4.1 A, both splicing variants share
the first two coding exons. The coding sequence on the last exon of HAS3v1
is different and longer than the one of HAS3v2. However, HAS3v2 spans over
a longer part on the genome. The predicted protein topologies of both splicing
variants are shown in figure 4.1 B. The prediction is based on hydropathy plots
[Weigel et al. 1997]. Accordingly, HAS3v1 is predicted to have seven transmem-
brane domains, while HAS3v2 has only two. The intracellular loop between the
2nd and the 3rd transmembrane domain (66-383AA) of HAS3v1 is predicted to
be the catalytic domain, through which hyaluronan is synthesized. The puta-
tive catalytic domain is based on the in silico evolutionary homologous analysis.
HAS3v2 contains part of the catalytic domain (66-246AA) followed by a 35AA
long c-terminal tail that is unique for HAS3v2..
4.1.2 Glycosyl transferase 2 domain.
Whether HAS3v2 contains a putative catalytic center was tested in silico by
pfam (http://pfam.sanger.ac.uk/). Pfam is a database of protein families that
includes their annotations and multiple sequence alignments generated using
hidden Markov models. As shown in figure 4.2 A, the active glycosyl transferase
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Figure 4.1: Genomic and topological structure of human HAS3 isoforms
(A): genomic structure of human HAS3 splicing variants; (B): predicted topological protein struc-
ture of HAS3 splicing variants. The orange intracellular part of HAS3v1 and HAS3v2 are identi-
cal in AA sequence. The blue part on the c-terminal of HAS3v2 indicates its unique AA compo-
sition.
54
Results
Figure 4.2: In silico prediction of glycosyl transferase activity of HAS3v2
(A): functional domain prediction using pfam. Glycosyl transferase 2 domain (red block) is
detected from HAS3v1 and HAS3v2 (grey line indicates the AA sequence).; (B): 3D protein
structure prediction of the active center of HAS3v1 and HAS3v2. The green overlay indicates
the identical structure between HAS3v1 and HAS3v2. The yellow part is unique for HAS3v1
and pink part for HAS3v2 respectively.
2 domain was predicted for the amino acid sequence between AA 88 to AA 124
of both HAS3v1 and HAS3v2. This domain is localized within the predicted
catalytic centers of HAS3v1 and HAS3v2. The glycosyl transferase 2 domain is
the only enzymatic domain found in HAS3v1. Further, HAS3v1 is known to be
an active hyaluronan synthase.
In addition, 3D protein structures of both the catalytic loop of HAS3v1 and
the c-terminal intracellular tail of HAS3v2 were simulated using the software
hhpred (http://toolkit.tuebingen.mpg.de/hhpred/). These two protein structures
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were overlapped to analyze the structural similarity. As shown in figure 4.2 B,
the overlap between the catalytic centers from HAS3v1 and HAS3v2 is indi-
cated by the green color. Of note, the glycosyl transferase 2 domain is localized
on this green overlap as well. The pink part is unique for HAS3v2 while the
yellow part only exists in HAS3v1. Therefore, HAS3v2 might also function as
active hyaluronan synthase, despite its truncated structure and the lack of 5
transmembrane domains compared to HAS3v1.
4.2 Subcellular localization of human HAS3v2
4.2.1 Localization of HAS3v2 as analyzed by YFP-HAS fu-
sion protein.
Figure 4.3: Schematic structure of YFP-HAS fusion protein
(A): Genomic structure of human HAS3; (B): Scheme of YFP-HAS fusion protein
To address the subcellular localization of HAS3v2, YFP fusion proteins were
constructed. Figure 4.3 B shows the scheme of the plasmids. The CMV pro-
moter was used to drive the expression of YFP-HAS fusion proteins. RT-PCR
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Figure 4.4: HA quantification of extracellular secretion after YFP-HAS transfections
After transfection of HEK 293 cells, HA concentration was determined from cell culture super-
natant and normalized to cellular protein. In addition, 4-MU was used to inhibit HA synthesis.
Data are normalized to YFP Control. white bar: without 4-MU; black bar: with 0.5 mM 4-MU;
representative result out of triplicate experiment
was performed to obtain the full-length coding sequences of human HAS2,
HAS3v1 and HAS3v2 from total RNA of human smooth muscle cells. After-
wards, these sequences were cloned to fuse onto the 3’ end of YFP coding
sequence. The YFP-HAS chimera were over-expressed by transfecting the tar-
get cell hosts. The mock YFP expression vector served as control.
4.2.2 Transfection of YFP-HAS2 and YFP-HAS3 causes in-
creased HA in culture medium.
HEK 293 cells were selected as the host, in which YFP, YFP-HAS2, YFP-
HAS3v1 and YFP-HAS3v2 stablely overexpressed. The stable cell clones were
selected by puromycin beginning 24 hours after transfection. Colonies were
picked after 7 days of selection. The culture medium from these stable cell
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Figure 4.5: Subcellular localization of YFP-HAS fusion proteins
HEK 293 cells were transfected with YFP-HAS expression vectors and selected by promycin.
After isolation of stable clones, the expression of YFP fusion proteins were monitored by fluo-
rescence microscopy. Upper panel: phase contrast; lower panel: YFP channel. White arrows
indicate the microvilli structure on plasma membrane. Magnification: 400 ×
lines were collected for measuring HA secretion within 24 hours after medium
change. As is shown in figure 4.4, overexpression of YFP-HAS2 and YFP-
HAS3v1 induced extracellular HA up to 7 fold within 24 hours compared to YFP
mock control. The overproduction of HA could be attenuated by a specific in-
hibitor of hyaluronan synthases, namely 4-methylumbelliferone (4-MU). This in-
dicates that the YFP-HAS fusion proteins are active. However, overexpressing
YFP-HAS3v2 in HEK cell did not lead to increased HA secretion of HA in the
cell culture medium.
4.2.3 The subcellular localization of HAS3v2 is different from
HAS3v1 and HAS2.
The sub-cellular expression patterns of the YFP-HAS fusion proteins were ex-
amined by fluorescent microscopy. As shown in figure 4.5, the YFP mock con-
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struct shows ubiquitous YFP signal throughout the cell, as well as in the nu-
cleus. The expression patterns of YFP-HAS2 and YFP-HAS3v1 are similar.
Importantly, these two YFP fusion proteins are expressed at the circumstance
of the cell indicating the plasma membrane localization. In addition, increased
microvilli structures can also be observed (indicated by white arrow in figure
4.5). YFP-HAS2 and YFP-HAS3v1 were also detected in cytosol. However, the
fluorescent signal of YFP-HAS3v2 was localized in the cytosol characterized
by a network-like structure. Furthermore, there was no clear signal surround-
ing the cell, suggesting that the YFP-HAS3v2 may not expressed in the plasma
membrane.
4.2.4 Subcellularly, HAS3v2 does reside the ER and Golgi.
A plasma membrane marker was introduced to evaluate whether HAS3v2 is
localized in the plasma membrane. As shown in figure 4.6 A, in case of YFP-
HAS3v1 and YFP-HAS2 the YFP signal surrounding the cell overlapped with the
cy3 signal from the plasma membrane marker. However, there was no overlap
between the YFP signal from YFP-HAS3v2 and the plasma membrane marker.
This illustrates that, unlike HAS2 and HAS3v1, HAS3v2 is not present in the
plasma membrane. The YFP mock control shows ubiquitous signal inside the
cell.
Endoplasmic reticulum (ER) has an interconnected-network structure in the
cell, which is similar to the YFP-HAS3v2 expression pattern. HAS3v2 also has
two predicted hydrophobic transmembrane domains. Therefore, it is suspected
that HAS3v2 might be present in the ER. Cy3-ER marker was utilized for the co-
localization experiment. In figure 4.6 B, the YFP mock control showed overlap
with the ER-Golgi marker, which was expected due to the ubiquitous localization
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Figure 4.6: Co-localization analysis using plasma membrane and ER marker
(A): Cy3 conjugated plasma membrane marker; (B): Cy3 conjugated ER marker. Magnification:
400 ×
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inside the cell. Also, partial overlap of the ER marker and the accumulated
intracellular YFP signal from YFP-HAS2 and YFP-HAS3v1 was observed. The
phase contrast pictures revealed that the condensed intracellular YFP signal of
both YFP-HAS2 and YFP-HAS3v1 can be tracked to the golgi apparatus. This
might be explained by the fact that both HAS2 and HAS3v1 are processed in
the golgi and further transported to the plasma membrane. Importantly, the
subcellular interconnected-network-like expression pattern of HAS3v2 showed
a complete overlap with the ER marker, which suggested that HAS3v2 is indeed
localized in the ER.
4.3 Biological function of HAS3v2
4.3.1 Overexpression of HAS3v2 causes a increase of intra-
cellular hyaluronan.
Due to the ER localization of HAS3v2, HA-ELISA was performed in order to
quantify the extracellular, pericellular as well as the intracellular hyaluronan of
YFP-HAS3v2 compared to YFP transfected cells. For the extracellular and peri-
cellular hyaluronan, there were no significant differences between YFP-HAS3v2
and YFP mock. Yet, there was significantly more intracellular hyaluronan from
YFP-HAS3v2 compared to YFP mock (figure 4.7 A).
Subsequently, the HAS3v2 was overexpressed in human skin fibroblast us-
ing the lentiviral vector. Five days after transduction, the samples were col-
lected for quantifying hyaluronan in the three different cellular compartments.
As shown in figure 4.7 B, significant induction of intracellular hyaluronan oc-
cured in response to the overexpression of HAS3v2 compared to pCL1 mock.
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Figure 4.7: HAS3v2 increases intracellular HA.
Extra-, peri- and intracellular HA from stablely transfected HEK cells (A) and lentiviral trans-
ducted skin fibroblasts (B) were quantified by HA ELISA. Immunocytochemical analysis of in-
tracellular HA from lentivirally transduced skin fibroblasts (C): pCL1 mock, permeabilized (I);
overexpression of HAS3v2, permeabilized (II); overexpression of HAS3v2, non-permeabilized
(III); overexpression of HAS3v2, streptomyces hyaluronidase digestion after permeabilization
(IV). The HAS3v2 overexpression leads to a new localization pattern of intracellular HA (white
triangle) compared to pCL1 mock (white star).
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No statistically significant differences of extracellular and pericellular hyaluronan
were observed between pCL1 mock and the overexpression of HAS3v2.
Beside the HA quantification by ELISA, intracellular hyaluronan was stained
using the biotinylated HABP (HA binding protein). Skin fibroblasts were trans-
ducted either by pCL1 mock or HAS3v2 lentivirus prior to intracellular HA stain-
ing. Skin fibroblasts were fixed on the glass cover slides five days after trans-
duction with either pCL1 mock (I) or HAS3v2 overexpression (II) lentiviruses.
Then, the cells were digested by hyaluronidase before permabilizing the cell
membrane. This procedure removes the extra- and pericellular hyaluronan. Af-
terwards, the cells were stained by biotin-HABP and cy3-streptavidin. Hoechst
33342 is used to indicate the cell nuclei. Images were taken by using confo-
cal laser microscopy. As shown in figure 4.7 C, overexpression of HAS3v2 (II)
in human skin fibroblast led to enhanced intracellular HA compared to pCL1
(I) mock control. To prove the specificity of intracellular staining, two nega-
tive controls were included. The HAS3v2 overexpressing skin fibroblasts were
stained either without permeabilization of the cell membrane (III) or after strep-
tomyces hyaluronidase digestion of permeabilized cells (IV). Both negative con-
trols showed no positive staining, which confirms the specificity of the stainings
in (I) and (II).
4.3.2 HAS3v2 might be an active intracellular hyaluronan syn-
thase.
Intracellular HA may arise from both endocytosis and de novo synthesis [Evanko
and Wight 1999]. Further, intracellular HA also accumulates on the outer mem-
brane of ER. Therefore, HAS3v2 might be a promising candidate for an intra-
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cellular hyaluronan synthase. The modified HAS enzymatic capture assay was
used to investigate whether HAS3v2 can mediate HA synthesis [Kyossev and
Weigel 2007]. As illustrated in figure 4.8 A, hyaluronan synthases form a com-
plex with HA after synthesis. Biotinylated HABP was used to bind the HA of
the HA-HAS complex so that the whole complex (bHABP-HA-HAS) can be co-
immunoprecipitated by streptavidin conjungated agarose. As negative control,
Streptomyces hyaluronidase was used to digest the HA from the complex be-
fore incubating with biotinylated HABP. After digesting the HA by hyaluronidase,
hyaluronan synthases can not bind to the agarose anymore. As a result, no
co-immunoprecititated HAS can be detected.
Microsomes are the raw membrane fraction of the cells, which contains
mainly ER and golgi apparatus. Microsomes, which were isolated from YFP,
YFP-HAS3v1 and YFP-HAS3v2 transfected HEK 293 cells were incubated with
UDP-glucoronic acid and UDP-acetyglucosamine overnight. Subsequently, the
modified HAS enzymatic capture assay was performed as described above.
The proteins linked to the agarose were washed out by protein lysis buffer for
western blot. YFP antibody was used to detect the YFP epitope of the fusion
proteins. The result is shown in figure 4.8 B. YFP is not immunoprecipitated indi-
cating the specificity of the experiment. However, both YFP-HAS3v1 and YFP-
HAS3v2 were co-precipitated. The YFP-HAS3v1 fusion protein has a predicted
molecular weight of 90 kDa, which has in line with the signal of the immunoblot
shown in figure 4.8 B. The double bands formed in case of YFP-HAS3v1 might
be due to posttranslational modifications. This also suggests that c-terminal
truncation of HAS3v1 does not affect its enzymatic activity. The molecular
weight of YFP-HAS3v2 fusion protein is 58 kDa, which was also detected on the
YFP westernblot after the enzymatic capture assay. The co-precipitations were
prevented by digesting the HA-HAS complex with hyaluronidase as a negative
64
Results
Figure 4.8: HA-HAS3v2 complex is detected by modified HAS enzymatic capture assay
(A): Scheme of modified HAS enzymatic capture assay. Further details are given in section 3.14;
(B): Immunoblot analysis of the YFP epitope with the protein samples from modified enzymatic
capture assay. Microsomes from YFP (1), YFP-HAS3v1 (2, 3) and YFP-HAS3v2 (4, 5) stably
transfected HEK 293 cells were used for the assay. Hyaluronidase digestion (lane 2, 4) was
performed prior to addition of biotinylated HABP.
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control. This indicates that HAS3v2 might be an active hyaluronan synthase.
4.4 HAS3v2 in esophagus adenocarcinoma
4.4.1 Upregulation of HAS3v2 in esophageal adenocarcinoma
(EAC)
Biopsies were collected from patients who suffered from either esophageal
squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC). Af-
ter the surgical intervention, samples were stored immediately in liquid nitro-
gen. Total RNA was isolated and the relative expression levels of hyaluronan
synthase isoforms were quantified by realtime RT qPCR. All the data were then
normalized to the average of the mucosa group. As shown in figure 4.9, HAS3v1
is upregulated in ESCC compared to mucosa and other HAS isoforms remain
constant. In contrast, only HAS3v2 was significantly upregulated in the ADC
group compared to mucosa.
4.4.2 In EAC, the expression level of HAS3v2 is positively
correlated with the TNM tumor staging.
HAS3v2 is upregulated in EAC compared to mucosa. Therefore, it appeared im-
portant to examine whether the induction of HAS3v2 was correlated with tumor
progression. Tumor stage and grading were classified by routine histopatho-
logic assessment according to the UICC (Union Internationale Contre le Can-
cer) Classification for Malignant Tumors. Then, the relative expression levels of
HAS3v2 from each tumor sample was plotted against the respective its TNM
66
Results
Figure 4.9: Expression level of HAS isoforms in human ESCC and EAC compared to
mucosa
mRNA expression was determined by RT-qPCR from tumor material removed during surgery.
As control, healthy mucosal tissue from the circumstance of the excised tumors was used. One-
way ANOWA method was used for statistic analysis. n=13 for mucosa control, 12 for ESCC and
40 for EAC, respectively.
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Figure 4.10: HAS3v2 expression level is positively correlated with EAC TNM tumor stag-
ing
mRNA expression was determined by RT-qPCR from tumor material removed during surgery.
As control, healthy mucosal tissue from the circumstance of the excised tumors was used. Cor-
relation coefficient method was used for statistic analysis. n=5 for T1, 16 for T2, 17 for T3 and 2
for T4, respectively.
tumor staging. As is shown in figure 4.10, HAS3v2 expression correlates with
increasing tumor staging. Correlation coefficient method was used for statistic
analysis.
4.5 Functinal analysis of HAS3v2 in EAC cells in
vitro
4.5.1 Overexpression of HAS3v2 in EAC cells leads to a pro-
proliferative phenotype in vitro.
HAS3v2 was strongly upregulated in EAC. Therefore, the functional analysis
of HAS3v2 was performed in EAC cell line, i.e. PT1590. PT1590 cells were
transduced with either pCL1 mock or HAS3v2 overexpression lentivirus. The
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proliferation assay was performed 5 days after transduction. As shown in figure
4.11 A, overexpression of HAS3v2 led to enhanced proliferation compared to
pCL1 mock transduced cells. Furthermore, growth curves were determined
by cell counting. Five days after transduction, the cells were re-plated at a
density of 1000 cells/cm2 in 12-well plates and were counted daily by using the
Neubauer chamber for 5 days after plating. As shown in figure 4.11 B, cells
overexpressing HAS3v2 grew significantly faster than pCL1 mock transduced
cells, which led to an increasing difference in cell number.
Figure 4.11: HAS3v2 overexpression leads to a pro-proliferative phenotype.
(A): Cell proliferation was measured by CyQUANT NF proliferation assay kit, (n=4); (B): Growth
kinetics were determined by cell counting, (n=4). * p < 0.05
4.5.2 ERK1/2 is phosphorylated in response to overexpres-
sion of HAS3v2.
As described in the previous section, HAS3v2 caused increased proliferation in
vitro. One hypothesis was that HAS3v2 causes intracellular HA accumulation
which in turn might induce intracellular signalling via RHAMM and activation of
MAP-kinase pathway. Therefore, we investigated the phosphorylation level of
ERK1/2, one of the MAP kinases, that directly interacts with RHAMM. Figure
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Figure 4.12: HAS3v2 enhances phosphorylation of ERK1/2.
PT1590 human EAC cells were lentivirally transduced with either pCL1 mock or HAS3v2 over-
expression, grown in 10 % FCS. The culture medium was changed to FCS-free medium 4 days
after transduction to eliminate the exogenous stimuli. Proteins were harvested for immunoblot
24 hours after FCS-free treatment. (A): Representative immunoblot of phosphorylated ERK and
total ERK; intensity quantification of ERK (B) and phospho-ERK (C) immunoblots using fluores-
cent secondary antibodies and the Licor Odyssie imager. β-tubulin was taken as loading control
(n=3). * p < 0.05
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4.12 A shows that overexpression of HAS3v2 increased the phosphorylation
of ERK1/2 dramatically. The increase in phosphorylation is more than 2 fold
(shown in figure 4.12 C).
4.5.3 HAS3v2 enhances cell adhesion by inducing both ex-
pression and phosphorylation of focal adhesion kinase
(FAK).
Furthermore, the cell adhesion was determined after overexpressing HAS3v2
in PT1590. Five days after transduction, cells were plated in the 96 well plates
and were washed after 30 minutes. Cells attached to the plate were then stained
with crystal violet. The absorption was measured by UV spectrometry at 540
nm. As shown in figure 4.13 A, overexpession of HAS3v2 causes increased cell
adhesion ability. This might be due to the enhanced phosphorylation of focal
adhesion kinase (FAK) as evidenced by western blotting (figure 4.13 B, D).
4.6 Functional analysis of HAS3v2 in xenograft model
in vivo
4.6.1 Overexpression of HAS3v2 promotes tumor growth in
vivo.
In order to study the physiological and pathological function, we overexpressed
HAS3v2 in PT1590 cell with the lentiviral vector as described for the in vitro
analysis. The mock vector, which led to the overexpression of EGFP, was used
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Figure 4.13: HAS3v2 enhances cell adhesion by inducing both expression and phospho-
rylation of focal adhesion kinase (FAK).
PT1590 human EAC cells were lentivirally transduced with either pCL1 mock or HAS3v2 over-
expression, grown in 10 % FCS. The culture medium was changed to FCS-free medium 4
days after transduction to eliminate the exogenous stimuli. Proteins were harvested for im-
munoblot 24 hours after FCS-free treatment. (A): Cell adhesion assay, (n=4); (B): Represen-
tative immunoblot of phosphorylated FAK and total FAK; intensity quantification of FAK (C) and
phospho-FAK (D) immunoblots using fluorescent secondary antibodies and the Licor Odyssie
imager. β-tubulin was taken as loading control (n=3). * p < 0.05
72
Results
Figure 4.14: Xenograft model of EAC
PT1590 human EAC cells were lentivirally transduced with either pCL1 mock or HAS3v2 over-
expression, grown in 10 % FCS. For xenografting, 1 × 106 cells were subcutaneously and
bilaterally into the flanks of NMRI nu/nu mice at the age of 10 weeks. (A)Timecourse of tumor
numbers; (B): Cumulative tumor volume as determined by digital caliper; n=9 for pCL1 mock
and n=11 for HAS3v2 overexpression.
as control. NMRI nu/nu mice were used for subcutaneous tumor formation. 1 ×
106 PT1590 cells were injected into both flanks, and the mice were monitored for
35 days after xenografting. During the experimental period, tumor volumes were
measured every 3 or 4 days. As illustrated in figure 4.14 B, the HAS3v2 over-
expression group shows larger cumulative tumor volume compared to the mock
group. Furthermore, tumors from the HAS3v2 overexpression group became
visible earlier than the mock group. However, the number of tumors growing
from both groups were similar 35 days after inoculation (figure 4.14 A).
After 35 days, the experiment was ended and tumor volume and tumor wet
weight were determined. The results are shown in figure 4.15. The average
tumor volume of group overexpressing HAS3v2 is significantly larger than of
the mock group. Also, overexpressing HAS3v2 increases the tumor wet weight.
Representative image from each group is shown in figure 4.15 C. These results
suggest that the progression of HAS3v2 overexpressing tumors is faster than of
the mock transduced tumors.
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Figure 4.15: HAS3v2 increases tumor volume and tumor wet weight in the xenograft
model.
PT1590 EAC cells were lentivirally transduced and xenografted into NMRI nu/nu mice. After
35 days, mock control (pCL1) and HAS3v2 overexpressing (oeHAS3v2) tumors were removed
and tumor progression was compapred. (A)Tumor volume was determined by digital caliper.
(n=9-11); (B): Tumor wet weight (n=9-11); (C): Representative tumor image from each group. *
p < 0.05
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Figure 4.16: Relative quantification of HAS3v2 mRNA from xenograft
Total RNA was isolated from xenograft tumors derived from mock and HAS3v2 overexpression
transduced PT1590 cells. After 35 days, NMRI nu/nu mice were sacrificed to remove tumors
and gene expression was determined by RT-qPCR. (n=9-11). * p < 0.05
4.6.2 Overexpression of HAS3v2 in tumor cells leads to in-
duction of HAS3 in stromal cells.
RNA from the xenograft tumor was isolated for realtime qPCR analysis. The
tumor contains both human cancer cells and mouse stromal cells. Therefore,
species specific primer pairs were designed to quantify the gene regulation of
tumor and stroma separately. As shown in figure 4.16, HAS3v2 mRNA remains
highly induced in tumor of the overexpression group at 35 days after innocula-
tion. The expression level of HA related genes, namely HAS1, HAS2, HAS3v1,
Hyal1, Hyal2, and HA receptors CD44s and RHAMM, were also quantified. For
the quantification, species specific primers were used that allowed to distinguish
between murine/stroma gene expression and human/tumor gene expression.
In the tumors, the indicated genes were not significant regulated in response
to HAS3v2 overexpression. However, murine HAS3v1 in the stroma of HAS3v2
overexpressing tumors was stimulated up to about 6 fold compared to the pCL1
mock group (figure 4.18, 4.17).
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Figure 4.17: Species specific expression profile of HA-associated genes in the xenograft,
part A
Total RNA was isolated from xenograft tumors derived from mock and HAS3v2 overexpression
transduced PT1590 cells. After 35 days, NMRI nu/nu mice were sacrificed to remove tumors
and gene expression was determined by RT-qPCR. Left column: human/tumor gene expression;
right column: murine/stroma gene expression(n=9-11). * p < 0.05
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Figure 4.18: Species specific expression profile of HA-associated genes in the xenograft,
part B
Total RNA was isolated from xenograft tumors derived from mock and HAS3v2 overexpression
transduced PT1590 cells. After 35 days, NMRI nu/nu mice were sacrificed to remove tumors
and gene expression was determined by RT-qPCR. Left column: human/tumor gene expression;
right column: murine/stroma gene expression(n=9-11). * p < 0.05
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Figure 4.19: Affinity histochemical analysis of HA in xenograft tumors
PT1590 EAC cells were lentivirally transduced and xenografted into NMRI nu/nu mice. After 35
days, mock control (pCL1) and HAS3v2 overexpressing (oeHAS3v2) tumors were removed and
analyzed with respect to HA accumulation by affinity histochemistry using biotinylated HABP.
(n=9-11). Representative image from each group were selected. Magnification: 100 ×.
4.6.3 HA content in stroma is elevated in the HAS3v2 over-
expression group.
Xenograft tumors were also analyzed by immunohistochemistry. Biotinylated
HABP was used to detect hyaluronan in immunohistochemical analysis. As
shown in figure 4.19, more HA was detected in the stroma of HAS3v2 over-
expressing tumors compared to the mock control tumor. Tumorial associated
hyaluronan showed no obvious difference between the HAS3v2 and the mock
group. The accumulation of HA in stroma could be the consequence of HAS3v1
upregulation in murine stroma cells as shown in figure figure 4.18 and 4.17.
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Figure 4.20: Immunohistochemical analysis of proliferation in xenograft tumor
PT1590 EAC cells were lentivirally transduced and xenografted into NMRI nu/nu mice. After
35 days, mock control (pCL1) and HAS3v2 overexpressing (oeHAS3v2) tumors were removed
and analyzed with respect to proliferation rate by immunohistochemistry. Ki67 was stained as a
proliferation marker. Cells, which are positive for the staining, indicate that they are in G1, S, G2
or M phase of the cell cycle. (n=9-11). Representative image from each group were selected.
Magnification: 100 ×.
4.6.4 HAS3v2 induces proliferation in vivo.
In vivo proliferation rate was determined by immunohistochemical staining of
the proliferation marker, Ki 67. Figure 4.20 shows that there were more Ki 67
cells after HAS3v2 overexpression compared to the mock group suggesting that
HAS3v2 is also pro-proliferative in vivo.
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4.7 Epidermal growth factor receptor (EGFR) sig-
nal cascades regulates the expression of HAS3v2.
4.7.1 EGF induces HAS3v2 mRNA expression in EAC cells.
EGF signaling plays an important role in the progression of different types of
cancers including esophageal cancer. Therefore, we investigated whether the
EGF signaling pathway may influence the expression of HAS3v2. PT1590 cells
were starved in serum-free medium 24 hours before stimulation. Then, PT1590
cells were stimulated by epidermal growth factor with and without Cetuximab,
a blocking antibody of the EGF receptor. Total RNA was harvested 4 hours
and 24 hours after induction. As shown in figure 4.21, there was no significant
regulation of HAS3v2 by EGF at 4 hours. However, 24 hours after EGF stim-
ulation, strong upregulation of HAS3v2 was observed. This upregulation was
completely blocked by Cetuximab. This result suggests that the EGFR signal
cascade is able to regulate the HAS3v2.
4.7.2 The expression levels of EGFR and HAS3v2 are posi-
tively correlated in EAC.
EGFR is a member of ErbB family, which consists of four structurally related
receptor tyrosine kinases. Overexpression or overactivity of EGFR has been
shown to be associated with a number of cancers, including lung cancer and
esophageal cancer. qPCR was performed to measure the EGFR mRNA ex-
pression level of the EAC samples introduced in section 4.4.2. For quantifica-
tion, the data were normalized to the expression level of mucosa. Figure 4.22
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Figure 4.21: EGF stimulates HAS3v2 expression in vitro.
PT1590 EAC cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) or EGF
(10 ng/ml) plus Cetuximab (10 ng/ml) for 4 and 24 hours. HAS3v2 expression was determined
by RT-qPCR. HAS3v2 mRNA expression was quantified for 4 hours after (A) stimulation and 24
hours after stimulation (A). Relative expression data was normalized to control. (n=6). p < 0.05
Figure 4.22: mRNA expression level of EGFR in relationship to TNM staging in human
EAC.
mRNA expression was determined by RT-qPCR from tumor material removed during surgery.
As control, healthy mucosal tissue from the circumstance of the excised tumors was used.
Correlation coefficient method was used for statistic analysis. n=5 for T1, 16 for T2, 17 for T3
and 2 for T4, respectively.
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Figure 4.23: mRNA expression levels of EGFR and HAS3v2 are correlated in human EAC.
mRNA expression was determined by RT-qPCR from tumor material removed during surgery.
As control, healthy mucosal tissue from the circumstance of the excised tumors was used.
Correlation coefficient method was used for statistic analysis. n=5 for T1, 16 for T2, 17 for T3
and 2 for T4, respectively. The correlation between EGFR and HAS3v2 is analyzed in both
mucosa group (A)and EAC group (B)
showed that the mRNA expression level of EGFR was related to the tumor stag-
ing. In addition, it was analyzed whether HAS3v2 and EGFR expression were
correlated in both mucosa and EAC specimens. For the EAC group, a positive
correlation between the expression level of HAS3v2 and EGFR was observed
(figure 4.23 A). However, HAS3v2 shows no correlation with the EGFR in the
mucosa group (figure 4.23 B). Taking together, the results suggested the EGF
signaling pathway might be involved in the upregulation of HAS3v2 during EAC
progression in patients.
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Discussion
5.1 HAS3v2 might be an intracellular HA synthase.
5.1.1 Intracellular HA originates from both endocytosis and
de novo synthesis.
H Yaluronan is a high molecular weight glycosaminoglycan generally re-garded as an extracellular matrix molecule. The function of hyaluronan
is to promote cell locomotion and proliferation, and it plays a role in wound heal-
ing and developmental processes such as cell differentiation and migration. In
addition to its role in the extracellular matrix, hyaluronan has also been identified
in the cytoplasm and nuclei of cells from different tissues both in vivo and in vitro
[Margolis et al. 1976; London˜o and Bendayan 1988; Kan 1990; Ripellino et al.
1988; Eggli and Graber 1995; Evanko and Wight 1999; Furukawa and Terayama
1977, 1979; Ripellino et al. 1989; Hascall et al. 2004; Evanko et al. 2004]. Fur-
thermore, a number of hyaluronan binding proteins exist intracellularly that may
be important in regulation of the cell cycle or in gene transcription [Hofmann
et al. 1998; Grammatikakis et al. 1995; Deb and Datta 1996; Zhang et al. 1998].
For example, a vertebrate homologue of the cell cycle control protein CDC37
was cloned and found to bind hyaluronan [Grammatikakis et al. 1995], and an
intracellular form of the hyaluronan receptor, RHAMM, was shown to regulate
ERK kinase activity [Zhang et al. 1998].
The source of intracellular hyaluronan is not yet clear. Evanko and Wight
showed that hyaluronan could be taken up by endocytosis from the extracel-
lular space [Evanko and Wight 1999]. However, exogenous fluoresceinated
hyaluronan was confined to the endosomes and did not co-localize with the en-
dogenous hyaluronan network in the cytoplasm, suggesting that some of the
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Figure 5.1: Scheme of possible sources of intracellular hyaluronan
Intracellular HA originated from endocytosis (1) and possiblely also from intracellular de novo
synthesis (2). However, the site organelle where intracellular de novo synthesis of HA occurs is
not known. N, nucleus; PM, plasma membrane.
cytoplasmic hyaluronan must be derived from intracellular sources and not from
internalization of extracellular hyaluronan (figure 5.1). No evidence indicates
that HAS1, HAS2, and HAS3v1 can synthesize hyaluronan inside the cell, which
might be due to their plasma membrane localization. This rises the suggestion
that there is another active hyaluronan synthase localized inside the cell [Evanko
and Wight 1999].
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5.1.2 Evidence for the activity of HAS3v2
There are three hyaluronan synthase isoforms in human, namely HAS1, HAS2,
and HAS3 [Spicer et al. 1997b]. It is shown that all three HAS isoforms are local-
ized on the plasma membrane and synthesize extracellular hyaluronan [Weigel
et al. 1997]. Human hyaluronan synthases are transmembrane proteins that
contain seven putative transmembrane domains [Weigel et al. 1997]. The intra-
cellular loop between the 2nd and the 3rd transmembrane domain is predicted
to be the catalytic center [Yoshida et al. 2000]. A cysteine residue in the in-
tracellular loop is reported to be highly conserved from bacterial to mammalian
HAS and the modification of this cysteine can partially inhibit enzyme activity
[Weigel et al. 1997]. This suggests that the cysteine residue is critical for HAS
enzymatic activity.
Human HAS3 has two splicing variants, namely HAS3v1 and HAS3v2 [Sayo
et al. 2002; Monslow et al. 2003]. HAS3v2 is the shorter splicing variant of
HAS3 and consists of only 281 amino acids (553 AA for HAS3v1). HAS3v2
shows only 2 transmembrane domains in in silico analysis. Instead of intracel-
lular loop, HAS3v2 contains an intracellular c-terminal end of 215 AA in length,
which also contains the highly conserved cysteine residue (shown as black cir-
cle in figure 1.2). This raises the possibility that HAS3v2 might also be an ac-
tive hyaluronan synthase despite of its truncated size. In order to identify the
activity center in HAS3v2, protein functional analysis was performed in silico
using Pfam database [Finn et al. 2008]. The only functional domain, glycosyl
transferase 2 domain, is shared by both HAS3 splicing variants. This protein
domain is presented in all the active hyaluronan synthases found so far [Weigel
and DeAngelis 2007]. The glycosyl transferase 2 domain reaches from AA 88
to AA124 in both HAS3v1 and HAS3v2. This indicates the potential role of
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HAS3v2 in HA synthesis. In addition, we performed a 3D protein structure sim-
ulation for the intracellular loop of HAS3v1 and the intracellular c-terminal end
of HAS3v2, where the glycosyl transferase 2 domain is localized. The similarity
of 3D protein structure of HAS3 splicing variants was analyzed based on an
overlay algorithm [Soding 2005; Soding et al. 2005]. As shown in figure 4.2,
the green part indicates highly similar regions in protein conformation between
HAS3v1 and HAS3v2. Of note, the glycosyl transferase 2 domain is also local-
ized in this overlay.
Furthermore, in silico analysis revealed that HAS3v2 contains an evolution-
ary conserved cysteine which is proofed to be critical for the HAS enzymatic
activity. HAS3v2 also shares the glycosyl transferase 2 domain with other ac-
tive hyaluronan synthases. Furthermore, predicted 3D protein structures of the
putative active center from HAS3v1 and HAS3v2 are similiar. All these results
suggest that HAS3v2 could be an active hyaluronan synthase. Therefore, func-
tional studies of HAS3v2 were performed.
HAS3v2 is predicted to have only 2 transmembrane domains. However,
there are 7 transmembrane domains presented on the other HAS isoforms, i.e.
HAS1, HAS2 and HAS3v1 [Weigel et al. 1997]. Thus, it was not clear whether
HAS3v2 does also localize to the plasma membrane.
As reported, the N-terminal GFP-HAS2 and GFP-HAS3v1 fusion proteins
are active with respect to HA synthesis [Rilla et al. 2005; Kultti et al. 2006].
The first 261 AA sequence on the N-terminal of HAS3v2 protein is identical to
HAS3v1. Therefore, N-terminal YFP-HAS fusion proteins were constructed to
investigate the subcellular localization of HAS3v2 (shown in figure 4.3). The re-
sults indicated that HAS3v2 was not localized in the plasma membrane but on
the ER inside the cell. By protein translation, the predicted intracellular parts of
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Figure 5.2: Intracellular HA originates from both endocytosis and de novo synthesis.
Fluoresceinated hyaluronan (Green) is uptaken by endocytosis (A), and the cells were further
stained for intracellular HA (Red) (B). Bars = 25 µm. Images were taken from [Evanko and
Wight 1999]
the protein reside in the outer membrane part of ER. Therefore, the c-terminal
tail of HAS3v2 might extend of the outer ER membrane. If HAS3v2 was active,
it could synthesize HA on the ER membrane. This might provide an explanation
why intracellular HA was accumulated on the outer ER membrane but not in the
ER lumen [Evanko and Wight 1999]. Further, Evanko and Wight showed that
endocytosis of the exogenous hyaluronan is not the only source of intracellular
HA (figure 5.2). Hyaluronan remains attached to HA synthases during synthesis
[Kyossev and Weigel 2007]. Thereby, HA would remain localized on the outer
ER membrane during its synthesis by HAS3v2 and this could, at least partially,
compliment the intracellular HA localization pattern besides endocytosis of ex-
ogenous hyaluronan.
HAS3v2 was overexpressed in both HEK cells and skin fibroblasts. Then,
intracellular HA was quantified using HA ELISA. HAS3v2 caused increased in-
tracellular HA level in both cell lines. In addition, intracellular HA images were
taken by confocal microscope. The vesicular staining pattern in the cytosol
might due to the endocytosis of exogenous HA [Evanko and Wight 1999]. In
addition, a network-like intracellular HA signal (shown in figure 4.7, white arrow
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indicated compared to white star in mock group) was detected. This pattern
could not be explained by the endocytosis but might be due to the intracellular
de novo synthesis on the surface of ER by HAS3v2.
Hyaluronan is attached to the HAS during the synthesis [Kyossev and Weigel
2007]. Enzymatic capture assay experiments showed that a HA-HAS3v2 com-
plex exists in microsome preparations after supplementation with activated UDP-
sugers. However, the experiment was performed using microsomes isolated
from transfected HEK cells. Microsomes consisted of raw membranes, mainly
derived from ER and golgi apparatus. However, minor proportions of plasma
membrane could have been included. Therefore, hyaluronan could have also
been synthesized by HAS1, HAS2 and HAS3v1 originating from the plasma
membrane. One possible alternative explanation for the fact that HA-HAS3v2
complexes were detected is that the HAS3v2 binds to hyaluronan that was
synthesized by HAS1-3 from plasma membrane contamination. However, that
would require that HAS3v2 is at least a HA binding protein.
Currently, there are two known HA binding domain, namely LINK and GLA
domain [Day and Prestwich 2002]. Pfam and SMART (http://smart.embl-heidelberg.de/)
databases contain large collections of protein families [Finn et al. 2008; Schultz
et al. 1998; Ponting et al. 1999; Letunic et al. 2009]. Neither LINK nor GLA do-
mains were detected on HAS3v2 by analyzing through both pfam and SMART
databases. Further, overexpression of HAS3v2 led to increased intracellular
HA levels. Furthermore, if HAS3v2 was a HA binding protein, the only possible
explanation for increased intracellular HA is that HAS3v2 binds to hyaluronan
and protect it from hyaluronidase digestion. However, hyaluronidase digestions
completely eliminated hyaluronan on both permeabilized HAS3v2 overexpress-
ing skin fibroblasts and microsomes isolated from HAS3v2 transfected HEK cell.
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Thus, no protecting effect could be observed. Therefore, the enzymatic capture
assay strongly suggested the activity of HAS3v2 as hyaluronan synthase.
5.2 HAS3v2 is a potential tumor marker for EAC.
Esophageal cancer is the 6th most frequent cancer worldwide [Parkin et al.
1999]. Squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are the
two main subtypes of esophageal cancer [Blot 1995]. The prognosis for both
subtypes is rather poor with a 5-year relative survival rate between 11% and
15% [Lagarde et al. 2006]. Hyaluronan is known to be important for tumor pro-
gression in various cancer types [Auvinen et al. 2000; Ropponen et al. 1998;
Lipponen et al. 2001; Anttila et al. 2000; Seta¨la¨ et al. 1999]. HA synthesis is
correlated with the mRNA level of HAS isoforms. Therefore, we first analyzed
the regulation of HAS isoforms during tumor progression of both ESCC and
EAC.
HAS3v2 was highly upregulated in EAC, but not in ESCC, compared to
the mucosa group. However, the expression levels of other HAS isoforms re-
mained constant in EAC. Importantly, the HAS3v2 expression level was also
correlated to the tumor staging. This indicates that HAS3v2 is a potential tu-
mor marker for esophageal adenocarcinoma. In addition, HAS3v2 induced in-
tracellular hyaluronan accumulation, that often correlates with cell proliferation
[Evanko and Wight 1999]. Elevated cytosolic HA was detected in different can-
cer types [Corte et al. 2006; Vizoso et al. 2004; Ruibal et al. 2003]. Further,
intracellular HA binding protein RHAMM was reported to play important roles
in tumor progression [Giannopoulos and Schmitt 2006; Hus et al. 2008; Rein
et al. 2003; Tolg et al. 2003; Yamano et al. 2008; Zlobec et al. 2008]. These
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facts encouraged us to study the pathological function of HAS3v2 in esophageal
adenocarcinoma.
5.3 HAS3v2 is a candidate for an oncogene.
5.3.1 RHAMM pathway promotes tumor progression.
Both CD44 and RHAMM are hyaluronan receptors and play important roles in
regulating cell behaviors including tumor progression [Turley et al. 2002]. CD44
is a transmembrane protein, while RHAMM is located on the plasma membrane
as well as in the cytosolic compartment [Turley 1980]. The basal expression
level of RHAMM is low in normal tissue [Turley et al. 2002; Evanko et al. 2007;
Slevin et al. 2007]. However, it is reported to be highly expressed in several
advanced cancers [Giannopoulos and Schmitt 2006; Hus et al. 2008; Rein et al.
2003; Tolg et al. 2003; Yamano et al. 2008; Zlobec et al. 2008; Pujana et al.
2007]. According to the observations, one might speculate that excessive cy-
tosolic RHAMM might be activated by intracellular HA and in turn induce tumor
progression. Therefore, HAS3v2 regulated cell phenotype might be mediated
through the RHAMM signaling pathway.
5.3.2 HAS3v2 might induce the RHAMM signaling pathway
to regulate cell behavior.
Overexpression of HAS3v2 increases the proliferation rate both in vitro and in
xenograft experiments in nude mice. One reason is that the ERK1/2 kinase
phosphorylation was induced by overexpression of HAS3v2. ERK1/2 phospho-
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Figure 5.3: HAS3v2 might regulate cancer cell phenotype though RHAMM.
HAS3v2 overexpression leads to intracellular HA accumulation. The intracellular HA might bind
to RHAMM to induce phosphorylation of the ERK kinase. Phosphorylated ERK can induce
cell proliferation by activating the ERK signaling cascades. After binding to intracellular HA,
RHAMM can also translocate to the plasma membrane and interact with PDGF receptor in an
autocrine manner. Consequently, activated PDGF receptor can phosphorylate focal adhesion
kinase (FAK). This leads to improved cell adhesion. Phosphorylated FAK can also contribute to
the ERK phosphorylation to promote cell proliferation.
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rylation can be enhanced through the RHAMM signal cascade and thereby in-
duce the cell proliferation [Turley et al. 2002]. This leads to the hypothesis that
HAS3v2 can increase the intracellular HA and that intracellular HA can trigger
the RHAMM signaling pathway (shown in figure 5.3). After activation, ERK1/2 ki-
nase activates further signal cascades either by phosphorylation of downstream
targets like ELK1 or by translocating to the nucleus to initiate downstream pro-
tein expression and thereby promote cell cycle progression.
Protein export is considered to be dependent upon access to the classical
secretory pathway through the ER/Golgi route [Hathout 2007; Simpson et al.
2007]. Protein secretion through this route requires an N-terminal signal pep-
tide, that is responsible for most of the constitutive export of proteins [Hathout
2007; Simpson et al. 2007]. However, the primary structure of RHAMM lacks
this signal peptide for classical secretion [Maxwell et al. 2008]. Emerging evi-
dence reveals that some cytoplasmic proteins, e.g. RHAMM, can be exported
via an alternative mechanism that does not require the known structural secre-
tion cues (shown in figure 5.4) [Chivasa et al. 2006, 2005; Tjalsma et al. 2006].
Therefore, RHAMM may be activated by interacting with intracellular hyaluronan
and the activated HA-RHAMM complex is subsequently exported to the ECM
through the non-conventional protein export routes. Specifically, one RHAMM
splicing variant (splice variant xy) has been shown to interact with the PDGF re-
ceptor and to trigger the PDGF pathway. However it has not been demonstrated
directly whether HA binding to RHAMM is necessary for this transactivation of
the PDGF receptor [Zhang et al. 1998]. Activated PDGF signaling pathway can
stimulate FAK phosphorylation [Turley et al. 2002]. Therefore, intracellular ac-
tivation of RHAMM, translocation of RHAMM to the extracellular compartment
and activation of a growth factor receptor that crosstalks to focal adhesion com-
plexes and FAK may be responsible for the result presented here that HAS3v2
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Figure 5.4: Routes for non-conventional protein export
(A) Transporter channels. Cytoplasmic proteins can be exported through transporter-protein
channels and then captured by cell-surface counter receptors. As an example, FGF2 is shown
being exported through the ABC transporter and then captured by a heparin sulphate proteogly-
can [Nickel 2005; Prudovsky et al. 2008 Apr 1]. (B) Protein-release complex. Other cytoplasmic
proteins, such as epimorphin, associate with a protein-release complex that is composed of
S100A13 and synaptotagmin 1 that then binds to annexin 2. The epimorphin protein-release
complex is localized to, and flipped through, the cytoplasmic membrane in response to Ca2+
and phosphatidylserine. Released epimorphin then binds to αv-integrin, resulting in activation
of morphogenic signaling cascades [Radisky et al. 2003]. (C) Flippase activity. An alternate
route of export results from cytoplasmic proteins binding to transporter proteins that have intrin-
sic flippase activity when stimulated by phosphatidylserine [Daleke 2003]. (D,E) Exocytosis and
membrane blebbing. Additional mechanisms of non-conventional export include exocytosis (D)
and membrane blebbing (E). Cytoplasmic and/or nuclear proteins such as Ku are released by
exocytosis of exosomes [Paupert et al. 2007], but cytoplasmic proteins can also be exported in
vesicles formed by membrane blebbing [Huot et al. 1998]. Figure was taken from [Maxwell et al.
2008]
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overexpression causes elevated FAK phosphorylation and cell adhesion in vitro.
Phosphorylated FAK can further stimulate ERK phosphorylation and thereby
lead to an amplified ERK signaling response and proliferation. Taken together,
as a working hypothesis it is proposed that RHAMM is activated by intracellular
HA and then exported to the ECM to trigger the PDGF pathway through direct
interaction with PDGF receptor. Figure 5.3 shows the hypothetical scheme of
HAS3v2 mediated RHAMM signaling pathway. In future experiments, it should
be addressed if the effects of HAS3v2 overexpression are indeed dependent on
RHAMM and/or a growth factor receptor.
5.3.3 Stroma cells can also be influenced by HAS3v2 upreg-
ulation in cancer cells.
Immunohistochemical analysis revealed increased hyaluronan in the stroma but
not around cancer cells after xenografting HAS3v2 overexpressing EAC cells.
The expression level of HAS3v1 in stroma was upregulated by HAS3v2 overex-
pression in cancer cells as determined by mouse specific analysis of HAS3v1
mRNA expression. The upregulation of stromal HAS3v1 explained the increase
of stromal hyaluronan. One possible explanation for the induction of stromal
hyaluronan in this model is that the overexpression of HAS3v2 activated via
RHAMM the malignant phenotype of the xenografted EAC cells (shown in figure
5.5). These activated EAC in turn released factors such as growth factors or
cytokines that stimulated the stromal cells to express HAS3v1. In efficient path-
way how HAS3v1 is induced is the activation of NF-κB, which was confirmed by
promoter analysis [Monslow et al. 2003].
Quantitative PCR results indicated that the mRNA levels of HAS1, HAS2 and
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HAS3v1 in cancer cells are high enough to perform HA synthesis. However, by
affinity histochemistry the cancer cells were nearly all HA negative except the
outer layer of the cancer colonies that were in contact with stromal cells. The
HA poor phenotype could be explained by the hypothesis that the cancer cells
inside the tumor are lacking of the substrates for HA synthesis, namely UDP-
glucoronic acid and UDP-glucosamine. This may also explain why there was no
intracellular HA accumulation despite of strong overexpression of HAS3v2. Al-
ternatively, the tumor cells degrade hyaluronan and generate small hyaluronan
fragments that can not be stained by HABP.
Taking together, HAS3v2 induced tumor proliferation and cause changes in
the stroma environment that might also contribute to tumor progression.
5.3.4 Other intracellular hyaladherins might be involved in
HAS3v2 mediated signal transduction.
IHABP4 is a HA binding protein localized in the cytosol and nucleus [Huang
et al. 2000]. Upregulation of IHABP4 is observed in several cancer types [Ko-
barg et al. 1997]. IHABP4 interacts with RACK1 and regulates the cell survival
by inducing the protein kinase C pathway [Nery et al. 2004]. In addition, human
CDC37 was also identified to be an intracellular HA binding protein, whose ho-
mologue in Saccharomyces cerevisiae functions as a cell division cycle control
protein [Grammatikakis et al. 1995]. Furthermore, HABP1 is detected as an
intracellular hyaladherin as well, although it is found also on the plasma mem-
brane and thereby promote cell adhesion[Gupta et al. 1991; Gupta and Datta
1991; Muta et al. 1997; Dedio et al. 1998; Simos and Georgatos 1994]. HABP1
is highly expressed in various cancer types including esophageal adenocarci-
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Figure 5.5: HAS3v2 regulates both cancer and stromal cell phenotype though RHAMM
Overexpression of HAS3v2 in cancer cells induces cell proliferation and adhesion possiblely
through RHAMM signaling cascade. RHAMM can be activated by binding to intracellular HA and
translocated to the plasma membrane. There, activated RHAMM might also interact with the
PDGF receptor of stromal cells in a paracrine manner. This can induce the FAK phophorylation
in stromal cells. The transcriptional factor, NF-κB is a downstream target of the FAK signaling
pathway. Promoter analysis revealed NF-κB binding sites in the putative promoter region of
HAS3v1. After activation, NF-κB can translocate into the cell nucleus and promote HAS3v1
expression. Consequently, the upregulation of HAS3v1 in stromal cells leads to increased HA
in stromal part of the tumor.
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noma [Rubinstein et al. 2004]. Taking together, intracellular HA accumulation
by HAS3v2 overexpression may lead to interaction between hyaluronan and
those intracellular hyaladherins. Further experiments will be needed to prove
whether intracellular hyaladherins are involved in the observed biological effects
of HAS3v2.
5.3.5 Natural antisense RNA effect of HAS3v2
DERPC (Decreased Expression in Renal and Prostate Cancer) is a novel tu-
mor repressor gene. Human DERPC is localized on the chromosome 16q22.1
close to human HAS3. The expression level of DERPC is observed to be down-
regulated in prostate and renal cancer [Sun et al. 2002], but shows no regu-
lation during breast cancer progression [Green et al. 2009]. Overexpression
of DERPC leads to inhibited proliferation of prostate cancer cells in vitro [Sun
et al. 2002]. As shown in figure 5.6, mRNA of DERPC is complementary to the
mRNA of HAS3v2. Complementary RNA can cause RNA degradation due to
the mechanism of RNA interference (RNAi) [Werner et al. 2009]. This means
upregulation of HAS3v2 mRNA can lead to the downregulation of DERPC. Con-
sequently, cell proliferation rate might be enhanced due to the downregulation
of the proliferation repressor, DERPC.
5.4 Therapeutic implications for HAS3v2 in cancer
There are various alterations that affect EGF receptor (EGFR) in human cancers
[Henson and Gibson 2006]. EGFR is often mutated in the intracellular domain
rendering the tyrosine kinase constitutively active. Furthermore, some tumors
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Figure 5.6: HAS3v2 mRNA contains an antisense sequence against DERPC
The mRNA complementary region between HAS3v2 and DERPC is indicated as ‖. DERPC
consists of three splicing variants and all of them contain the complementary sequence against
HAS3v2.
increase the production of EGF-related growth factors leading to the persistent
activation of ErbB receptors, which play important roles in tumor progression
[Zhang et al. 2007].
Activation of the EGF receptor results in autophosphorylation of key tyro-
sine residues (figure 5.7) [Yarden 2001; Jorissen et al. 2003]. These tyrosine
phosphorylation sites allow proteins to bind through their Src homology 2 (SH2)
domains and lead to the activation of downstream signalling cascades including
the RAS/extracellular signal regulated kinase (ERK) pathway, the phosphatidyli-
nositol 3-kinase (PI3) pathway and the Janus kinase/Signal transducer and ac-
tivator of transcription (JAK/STAT) pathway [Kisseleva et al. 2002]. These path-
ways act in a coordinated manner to regulate cell behavior, e.g. cell survival.
EGF signaling pathway has become a therapeutic target for cancer treatment
[Zhang et al. 2007]. Cetuximab is a monoclonal antibody that prevents EGFR
signaling by binding to the ligand binding and receptor dimerisation domains and
is approved for treatment of colorectal and head-neck cancer [Van Cutsem et al.
2009; Egloff and Grandis 2009]. Further understanding of EGF signaling will
undoubtedly improve the understanding of oncogenesis and possibly provide
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Figure 5.7: Scheme of EGFR signaling pathway
Activation of the EGF receptor results in autophosphorylation of key tyrosine residues within the
EGFR. These tyrosine phosphorylation allow adaptor proteins to bind through their Src homol-
ogy 2 (SH2) domains and leads to the activation of downstream signalling cascades including
the RAS/extracellular signal regulated kinase (ERK) pathway, the phosphatidylinositol 3-kinase
(PI3) pathway and the Janus kinase/Signal transducer and activator of transcription (JAK/STAT)
pathway. These pathways act in a coordinated manner to promote cell survival.
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novel targets for therapeutic intervention.
EGF was identified here to stimulate the expression of HAS3v2 in vitro. Im-
portantly, the expression of HAS3v2 and EGFR in EAC patients are correlated.
This suggested that HAS3v2 could be regulated by EGFR signaling both in vitro
and in vivo. If HAS3v2 was a functional downstream target of EGFR in tumor, it
could contribute to increased cancer cell proliferation and adhesion in response
to EGF. Therefore, reduction of HAS3v2 expression might be one aspect of the
anti-cancer effect of EGF-inhibitory pharmacology. However, it might also be
considered that HAS3v2 could play a role for the occurrence of tumors resistant
to anti-EGF therapy and HAS3v2 could be targeted specifically.
5.5 Open questions and perspective
The data presented in this thesis give rise to many further questions that will be
addressed in future experiments.
1. HAS3v2 is shown to be located on the ER. However, no known ER reten-
tion signal was found on the AA sequence of HAS3v2 by in silico analysis.
Therefore, the mechanism of ER targeting of HAS3v2 nees to be identi-
fied.
2. Recombinant HAS3v2 could be purified from hyaluronan deficient organ-
isms, such as E. coli. HAS enzymatic capture assay with purified HAS3v2
protein could further proof that HAS3v2 is indeed an active hyaluronan
synthase.
3. Promoter analysis of HAS3v2 could discover regulatory mechanisms in
addition to EGFR signaling pathway.
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4. Specific antibody is required to detect HAS3v2 in protein expression.
5. It is impossible to knock down the HAS3v2 specifically by RNAi due to the
transcriptome structure. A neutralization antibody to HAS3v2 might be a
promising option to advance the experimental data on HAS3v2 function
and to test the potential therapeutic value.
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Summary
Summary
H Yaluronan is a large glycosaminoglycan mainly presented in the extra-cellular matrix as well as in the intracellular compartment. Hyaluronan is
synthesized by three hyaluronan synthase isoforms, namely HAS1, HAS2 and
HAS3. HAS3v2 is a smaller splicing variant of HAS3 with 281 AA in length.
Here, biological and pathological functions of HAS3v2 were investigated for the
first time.
HAS3v2 localizes on membrane of the endoplasmic reticulum as shown by
stable overpression of YFP-HAS3v2 fusion protein. Overexpression of HAS3v2
leads to increased intracellular hyaluronan. A HA-HAS3v2 complex was also
detected in microsomes of YFP-HAS3v2 overexpressing cells using the HAS
enzymatic capture assay. This indicated HAS3v2 is an intracellular hyaluronan
synthase or at least HA binding protein.
Esophageal cancer is one of the 10 most frequent tumor types worldwide,
which is distinguished into two major subtypes: squamous cell carcinoma (ESCC)
and adenocarcinoma (EAC). HAS3v2 is upregulated only in human EAC and
also correlated with TNM staging. This suggested that HAS3v2 is a potential
tumor marker for EAC. Lentiviral overexpression of HAS3v2 promotes cell pro-
liferation rate both in vitro and after xenografting of HAS3v2 overexpressing EAC
cells in nude mice . This phenotype was, at least partially, caused by enhanced
ERK1/2 kinase phosphorylation. HAS3v2 also stimulated the phosphorylation
of focal adhesion kinase (FAK) and improve EAC cell adhesion. Both phospho-
rylations could be the consequence of activated RHAMM signaling. Overex-
pression of HAS3v2 in cancer cells also stimulated HAS3v1 mRNA expression
in stromal cells of EAC xenograft, which led to increased stromal HA levels. The
stromal HA has been reported to provide microenvironment in favor for progres-
sion and metastasis.
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The expression of HAS3v2 in EAC was regulated by EGF pathway and the
blocking antibody of EGFR, Cetuximab, diminished the EGF-induced HAS3v2
upregulation. Furthermore, the mRNA expression of HAS3v2 and EGFR are
positively correlated in EAC patients.
Taken together, HAS3v2 promotes malignant tumor cell phenotype and could
be a diagnostic oncogene and a potential therapeutic target for EAC.
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Abbreviations
bHAbp BIOTINLYATED HA BINDING PROTEIN
Da DALTON
ECM EXTRACELLULAR MATRIX
ERK EXTRACELLULAR-SIGNAL REGULATED KINASE
EGF EPIDERMAL GROWTH FACTOR
EGFR EPIDERMAL GROWTH FACTOR RECEPTOR
FACS FLUORESCENCE ACTIVATED CELL SORTER
FAK FOCAL ADHESION KINASE
FGF FIBROBLAST GROWTH FACTOR
GAG GLYCOSAMINOGLYCAN
GlcA GLUCURONIC ACID
GlcNAc N-ACETYLGLUCOSAMINE
HA HYALURONAN
HAbp HA BINDING PROTEIN
HAS HYALURONAN SYNTHASE
HYAL HYALURONIDASE
IαI INTER-ALPHA-INHIBITOR
IHABP INTRACELLULAR HA BINDING PROTEIN
IL-1β INTERLEUKIN-1 BETA
KB KILLOBASE
MAP MITOGEN ACTIVATED PROTEIN
MAPK MITOGEN ACTIVATED PROTEIN KINASE
MEK MITOGEN ACTIVATED EXTRACELLULAR RESPONSE KINASE
MEKK-1 MAPK/ERK KINASE KINASE
MMP MATRIX METALLOPROTEINASE
NFκB NUCLEAR FACTOR KAPPA-B
PDGF PLATELET DERIVED GROWTH FACTOR
PI3K PHOSPHOINOSITIDE 3-KINASE
PKC PROTEIN KINASE C
RHAMM RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY
TLR TOLL-LIKE RECEPTOR
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